










Title of Dissertation: INVESTIGATION OF SMOOTH MUSCLE 
CELL DEATH AND GENOME 
INSTABILITY IN HUTCHINSON-
GILFORD PROGERIA SYNDROME   
  
 Haoyue Zhang, Doctor of Philosophy, 2016 
  
Dissertation directed by: Dr. Kan Cao 
Department of Cell Biology and Molecular 
Genetics 






Hutchinson–Gilford progeria syndrome (HGPS) is a severe human premature 
aging disorder caused by a lamin A mutant named progerin. Death occurs at a mean 
age of 13 y from cardiovascular problems. Previous studies revealed loss of vascular 
smooth muscle cells (SMCs) from large arteries in HGPS patient and mouse models, 
suggesting a causal connection between SMC loss and cardiovascular malfunction. 
The primary aim of this dissertation is to elucidate the molecular mechanisms 
underlying the massive SMC loss in HGPS. To study this, I develop an in vitro 
differentiation protocol to generate HGPS SMCs from induced pluripotent stem cells 
(iPSCs). My results indicate that HGPS SMCs exhibit a profound cell death 
phenotype, potentially recapitulating the in vivo SMC loss. Mechanistically, I find 
  
that HGPS SMCs bear deficient homologous recombination (HR). In addition, 
progerin accumulation strongly suppresses PARP1 and consequently triggers an 
activation of the error-prone non-homologous end joining (NHEJ) response during 
S/G2 phase. As a result, HGPS SMCs exhibit prolonged mitosis and mitotic 
catastrophe. 
Mis-regulated DNA damage response (DDR) is proposed to induce genome 
instability and various cellular phenotypes in HGPS, including HGPS SMC cell 
death. To better understand HGPS DDR misregulation, I examine HR and NHEJ in 
HGPS fibroblasts at different cell cycle phases. My analysis indicates that HR is 
deficient in S/G2 phase, whereas NHEJ, the dominant G0/G1 phase DDR pathway, is 
impaired in G0/G1 phase but active in S/G2 phase HGPS fibroblasts. The mis-
regulation of HR and NHEJ may jeopardize genome integrity in both G0/G1 and 
S/G2 phase HGPS cells. Mechanistic study reveals that H2AX, a crucial upstream 
DDR signal, is reduced in G0/G1 but normal in S/G2 phase HGPS cells, implicating a 
potential cause of the cell cycle-dependent NHEJ mis-regulation. Furthermore, this 
reduction is correlated with impaired ATM activation and loss of H3K9me3 in HGPS. 
Restoration of H3K9me3 by methylene blue treatment can stimulate ATM activity, 
improve H2AX signaling and rescue NHEJ in G0/G1 phase HGPS cells. This 
dissertation not only is the first mechanistic study on HGPS SMC loss but also 
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1.1 Hutchinson-Gilford progeria syndrome (HGPS) 
 
1.1.1 General description 
Hutchinson-Gilford progeria syndrome (HGPS) is one of the most devastating 
segmental aging diseases, initially characterized by Hutchinson and Gilford in 1886 
and 1897 respectively (Atkins, 1954). It is an extremely rare autosomal dominant 
disease, occurring at a rate of 1 in every 4-8 million of live births (Capell and Collins, 
2006; Merideth et al., 2008). HGPS associated premature aging phenotypes include 
nutrition deficiency independent growth impairment, bone abnormalities, joint 
contractures, sclerotic skin, lipodystrophy, alopecia and systematic cardiovascular 
dysfunctions(Gordon et al., 2007; Merideth et al., 2008). Patients with HGPS are  
born normal, while start to display the above phenotypes at about 12-24 months after 
birth and eventually die in their early teens (average 13 years old) due to 
cardiovascular diseases such as stroke or myocardial infarction (Gordon et al., 2007).  
 
1.1.2 Clinical features of HGPS 
In 2008, a natural history study performed by Merideth et al., comprehensively 
examined the pathological features in 15 HGPS patients. The study revealed that 
HGPS patients exhibited severe growth retardation after birth (Merideth et al., 2008). 
Between 2 to 10 years of age, an average gain of body weight was only 0.65kg per 
year in HGPS patients compared to 1.80kg in healthy children. Similarly, HGPS 
patients displayed an average gain of 3.58cm per year while healthy individuals 




faster weight and height growth with average gain of 1.01kg and 3.98cm per year 
respectively.  
Besides retarded growth, HGPS patients also showed a variety of 
musculoskeletal abnormalities such as abnormal peripheral joint motion range (every 
child older than 18 month of age), reduced spinal flexibility (11 out of 11 tested), 
stooped shoulder (11 out of 15), calcaneovalgus (9 out of 15), subluxed finger joints 
(7 out of 15), genu valgum (4 out of 15), kyphosis (3 out of 15) and calcaneo varus (1 
out of 15) (Merideth et al., 2008).  
Finally, Merideth et al. characterized a variety of cardiovascular abnormalities 
associated with HGPS (Merideth et al., 2008). For example, patients showed elevated 
systolic or diastolic blood pressure (7 out of 15), elevated pulse rate for age (5 of the 
oldest children), oxygen saturation (13 out of 13 tested), long QT intervals (5 out of 
15), thickened aortic valve (2 out of 15), distal anteroseptum ischemia (1 out of 15) 
and adventitia thickening (14 out of 15). Additionally, two previous postmortal 
studies on three HGPS patients revealed severe depletion of smooth muscle cells from 
aortic media, maladaptive vascular remodeling, intima thickening, disrupted elastin, 
deposition of extracellular matrix and sclerotic plaques induced stenosis (Stehbens et 
al., 2001; Stehbens et al., 1999). These phenotypes resulted in reduced cardiovascular 
functionality with age and are of particular interest given that the majority of HGPS 





1.1.3 Loss of vascular smooth muscle cells (SMCs) in HGPS 
A drastic phenotype that has repeatedly been observed in HGPS patients and 
animal models is the loss of media layer vascular smooth muscle cells (SMCs) in the 
major aortas. In the 2000s, two postmortem studies uncovered this phenotype in three 
HGPS patients (Stehbens et al., 2001; Stehbens et al., 1999) (Figure 1-1A). In an 
HGPS mouse model (BAC G608G), scientists observed a progressive loss of media 
layer smooth muscle cells in the descending aorta (Varga et al., 2006) (Figure 1-1B). 
This phenotype was later on recapitulated by a different HGPS mouse model, 
lmnaG609G (Osorio et al., 2011) (Figure 1-1C). Interestingly, vascular SMC loss has 
been long considered as a contribution to the development of cardiovascular disorders 
such as atherosclerosis (Bennett, 1999; Clarke et al., 2006). Notably, SMC loss has 
been implied to increase plaque vulnerability and induce vessel plaque rupture 
(Bennett, 1999; Clarke et al., 2006). These studies strongly suggest a role of SMC 
loss in HGPS cardiovascular pathology. However, the molecular mechanism 








Figure 1-1: Vascular SMC depletion in HGPS. (A). Postmortem study of the atherosclerotic aorta 
from a male HGPS patient (adapted from Stehbens et al. Cardiovascular Pathology 2001). (B). H&E 
analysis of 12 month old mice aorta indicates loss of vascular SMCs in BAC G608G transgenic mice 
(adapted from Varga et al. PNAS 2006). (C). DAPI staining of aortic arch indicates depletion of 
vascular SMCs in LmnaG609G mice (adapted from Osorio et al. Transl. Med. 2011). 
 
 
1.2 Causation: mutation in the LMNA gene 
 
1.2.1 HGPS associated LMNA mutation 
Given the fact that HGPS incidence did not show any family or sex preferences, 
it was initially difficult to genetically locate the mutated loci responsible for this 
specific disease. In 2003, Eriksson et al. successfully identified the prevalent 
(accounts for >80%) mutation for HGPS, using polymorphic microsatellite 
sequencing (Eriksson et al., 2003). This mutation is a spontaneous mutation in the 
LMNA gene on chromosome 1q21.2-q21.3 (Eriksson et al., 2003). It is a de novo 
mutation, which substitutes a single nucleotide (1824 C→T) in the exon 11 of the 
LMNA gene (Eriksson et al., 2003).  
Under normal circumstances, LMNA gene mainly encodes two protein products: 
lamin A and lamin C (Capell and Collins, 2006). As a type V intermediate filament 
protein, lamin A consists of two globular domains at N terminus and C terminus 
respectively as well as a central -helical rod domain. These domains allow lamin A 
to form homodimers and construct the nuclear lamina meshwork (see discussion in 
the next section) (Capell and Collins, 2006). At the C terminus of lamin A, there is a 




amino acid), which is indispensable for its maturation (Dechat et al., 2008; Zhang et 
al., 2013). With the CAAX motif, lamin A precursor undergoes a series of post-
translational modifications, in which, every step is strictly dependent on the previous 
one and eventually becomes mature lamin A (Dechat et al., 2008; McCord et al., 
2013; Zhang et al., 2013) (Figure 1-2A).  
Among these modifications, the initial step is farnesylation of the cysteine 
residue on the CAAX motif by farnesyltransferase (Ftase) (Dechat et al., 2008; Zhang 
et al., 2013) (Figure 1-2A). Then, the last three amino acids (-AAX) are removed by a 
zinc metalloproteinase called Zmpste24/FACE1 (Figure 1-2A). The remaining 
cysteine at C terminus then undergoes carboxymethylation mediated by 
isoprenylcysteine carboxyl methyltransferase (ICMT) (Zhang et al., 2013) (Figure 1-
2A). In the final step, the last 15 amino acids at C terminus including the farnesylated 
cysteine residue are removed by Zmpste24/FACE1, allowing the release of mature 
lamin A (Figure 1-2A). Mature lamin A, together with other nuclear lamina proteins 
(for example, B type lamins) form the nuclear lamina meshwork underneath the inner 






Figure 1-2: Post-translational processing of lamin A (A) and Progerin (B). Translation of the LMNA 
gene yields the prelamin A protein, which has the amino acids CSIM at the C-terminus. After 
farnesylation, a modification step that can be blocked by farnesyltransferase inhibitors (FTIs), the 
terminal three amino acids (SIM) are cleaved by the ZMPSTE24 endoprotease, and the terminal 
farnesylated cysteine undergoes carboxymethylation. A second cleavage step by the ZMPSTE24 
endoprotease then removes the terminal 15 amino acids, including the farnesyl group. This final 
cleavage step is blocked in progerin (B) (adapted from Zhang et al. Aging Cell 2013). 
 
In HGPS, the prevalent de novo mutation (1824 C→T) doesn’t change the 
original amino acid sequence (G608G) (Figure 1-3). However, this mutation 
introduces a cryptic splicing donor site in exon 11 of LMNA gene (Zhang et al., 2013) 
(Figure 1-3). This splicing donor site can be recognized by spliceosome during 
transcription and yield a 150 nucleotides in frame deleted mRNA, which is eventually 




2013) (Figure 1-3). Progerin completely abolishes the Zmpste24/FACE1 cleavage site 
in wild type prelamin A and therefore retains a farnesyl tail on the C terminus (Capell 
and Collins, 2006; Zhang et al., 2013) (Figure 1-2B). This farnesyl tail permanently 
anchors progerin at the INM and functions in a dominant negative fashion and 
disrupts nuclear lamina meshwork (Capell and Collins, 2006).  
 
 
Figure 1-3: Scheme of the classic HGPS mutation in LMNA gene. The LMNA wild type sequence is 
similar to consensus splice donor site, with only two nucleotides different (indicated by blue). The 
1824 cysteine in the wild type LMNA sequence was mutated into a thymine in HGPS, making the 
sequence closer to consensus splice donor site, with only one different nucleotide (indicated by blue). 
This mutation yields a cryptic splice donor site that can be recognized by spliceosome, resulting in a 
150 nt in frame deletion and a mutant protein termed progerin. 
 
 
1.2.2 Lamins and nuclear lamina 
As discussed above, LMNA gene mainly encodes two A type lamins: lamin A, 
lamin C (Zhang et al., 2013). These two proteins are the two major products of LMNA 




LMNA also encodes another two minor products: laminA10 and lamin C2 (Zhang et 
al., 2013). Lamin A10 was only reported to be expressed in colon, lung and breast 
carcinomas and lamin C2 was confined in male germ cells (Burke and Stewart, 2013; 
Capell and Collins, 2006; Hutchison, 2002). Besides A type lamins, there are three B 
type lamin proteins: lamin B1 encoded by LMNB1, lamin B2 encoded by LMNB2 and 
lamin B3 encoded by LMNB2. Whereas A type lamins are highly regulated 
throughout mammalian development and exclusively expressed in differentiated 
somatic cells, B type lamins are present ubiquitously in all cell types (Burke and 
Stewart, 2013; Capell and Collins, 2006).  
Both A and B type lamins belong to the type V intermediate filament proteins, 
which harbor a central -helical coiled-coil rod domain flanked by an amino (N) 
terminal globular head domain and a carboxy (C) terminal globular tail domain 
(Burke and Stewart, 2013; Capell and Collins, 2006). The central rod domain allows 
A or B type lamins to form parallel coiled-coil homodimers in a head-to-tail fashion, 
which then align laterally to form anti-parallel protofilaments (Burke and Stewart, 
2013; Capell and Collins, 2006). Eight protofilaments associate to form the 
intermediate filament structure (Capell and Collins, 2006). Lamin intermediate 
filaments then form a complex meshwork structure underneath the inner nuclear 
membrane (INM) termed nuclear lamina (Burke and Stewart, 2013). Nuclear lamina 
was initially considered to be little more than a structural apparatus, which only 
provides mechanical rigidity to support nuclear envelope. However, increasing 
evidences have recently revealed that nuclear lamina plays far more complex roles 




chromatin organization, cell cycle regulation, DNA replication, DNA damage repair 
and etc. (Burke and Stewart, 2013; Capell and Collins, 2006; Dechat et al., 2008; 
Hagting et al., 1999; Stuurman et al., 1998).  
Nuclear lamina in chromatin organization: nuclear lamina is suggested to 
provide anchoring points for chromatin domains and thereby regulate chromatin 
structure and histone modifications. The initial evidence supporting this idea is that A 
type lamins have been shown to directly interact with core histones and DNA through 
their tail domain (Andres and Gonzalez, 2009; Parnaik, 2008; Shoeman and Traub, 
1990; Taniura et al., 1995). A type lamins also indirectly bind to chromatin through 
interacting with lamin binding proteins such as Lap2a and barrier-to-autointegration 
(BAF) (Andres and Gonzalez, 2009; Dechat et al., 2009; Vlcek and Foisner, 2007). 
Microscopic study provided evidence that lamin A was able to interact with Lap2 
and locate heterochromatin to the nuclear envelope and potentially suppress gene 
transcription (Dechat et al., 2009; Reddy et al., 2008; Verstraeten et al., 2007). 
Moreover, evidence consolidating the functional importance of A type lamins in 
regulating chromatin structure come from reports on LMNA mutations. Loss of 
functions studies by knocking out lamin A from C. elegans or Drosophila have 
revealed abnormal chromatin organizations and developmental aberrations (Andres 
and Gonzalez, 2009; Parnaik, 2008). Cardiomyocytes from LMNA deficient (Lmna-/-) 
mouse have been shown to display dissociated heterochromatin from nuclear 
envelope (Nikolova et al., 2004). In addition, patient cells from multiple 
laminopathies (diseases caused by mutations associated with lamin encoding genes 




(MAD) and familial partial lipodystrophy (PFLD) all exhibit general loss of 
heterochromatin (Capanni et al., 2003; Capell and Collins, 2006; Filesi et al., 2005).  
Nuclear lamina in cell cycle regulation: at the onset of mitosis, nuclear lamina 
is phosphorylated by cyclin B/CDK1, which leads to its disassembly and allows 
mitotic spindles to interact with kinetochores (Hagting et al., 1999; Stuurman et al., 
1998). During this process, B type lamins are associated with disassembled nuclear 
envelopes while A type lamins are soluble and distributed evenly in the entire cell till 
the end of mitosis (Dechat et al., 2008; Goldman et al., 2002). Interestingly, it is 
unclear whether lamins play a role in nuclear envelope reassembly at the end of 
mitosis. There is evidence suggesting that de-phosphorylation of B type lamins by 
protein phosphatase 1 (PP1) that targets the nuclear envelope is a prerequisite for 
their reassembly (Steen et al., 2000; Thompson et al., 1997). Alternatively, there are 
also studies claiming that lamins don’t participate in nuclear envelope reassembly, but 
were transported into the nuclear vesicles around chromatins through nuclear pore 
complexes (Meier et al., 1991; Newport et al., 1990).   
Nuclear lamina in DNA replication: Both lamin A and B participate in 
regulating DNA replication. Unlike B type lamins which exclusively locates at the 
nuclear periphery and associates with the nuclear envelope, A type lamins are 
partially distributed in the nucleoplasmic region. This part of A type lamins are 
believed to play a role in the initiation of DNA replication (Dechat et al., 2008; 
Kennedy et al., 2000). In early S phase, the nucleoplasmic lamin A/C structures are 
associated with the replication origin sites in primary fibroblasts (Kennedy et al., 




antigen (PCNA) in the replication machinery in 3T3 cells (Dechat et al., 2008; Moir 
et al., 1994). Moreover, studies in Xenopus egg extracts revealed that immuno-
depletion of Xenopus major lamin XLB3 or introduction of XLB3 dominant negative 
mutant will inhibit DNA replication (Dechat et al., 2008; Meier et al., 1991; Newport 
et al., 1990). Introduction of dominant negative XLB3 mutant will result in 
redistribution of endogenous XLB3 foci along with PCNA and replication factor C 
(RFC) (Moir et al., 2000; Spann et al., 1997). Interestingly, re-establishment of 
normal lamin structure by transferring these foci into fresh extracts would resume 
DNA replication, suggesting an essential role of appropriate lamin structure in DNA 
replication (Moir et al., 2000). 
Nuclear lamina in DNA damage repair: several recent studies have enlightened 
the important role of lamin A/C in DNA damage repair. For instance, lamin A/C 
deficient cells exhibited elevated sensitivity to DNA inter-strand crosslinks (ICLs) 
and replication stress. When treated with ICLs agents, lamin A/C deficient cells 
displayed decreased recruitment of FANCD2 (a DNA damage repair factor), delayed 
H2AX (DNA double strand break marker) clearance and increased aberrant 
chromosomes (Singh et al., 2013). Similar effects were also observed in cells treated 
with hydroxyurea (a replication stress inducing agent) (Singh et al., 2013). In 
addition, lamin A also stabilizes DNA damage repair foci by engaging into 
chromosome through histone variant H2AX (Mahen et al., 2013).  Lamin A/C favor 
both non-homologous end joining (NHEJ) and homologous recombination (HR) 
DNA repair pathways by regulating DNA repair protein homeostasis. Depletion or 




(CTSL) mediated degradation of p53 binding protein 1 (53BP1) (an important NHEJ 
promoting factor) and transcriptional reduction of breast cancer 1 (BRCA1) and 
RAD51 (two key HR regulators) (Gibbs-Seymour et al., 2015). Consequently, 
deletion of lamin A/C inhibits both NHEJ and HR and renders persistent DNA 
breaks, chromosome aberrations and increased radio-sensitivity (Gibbs-Seymour et 
al., 2015; Singh et al., 2013). Mechanistically, 53BP1 binds to lamin A/C via its 
Tudor domain in undamaged human dermal fibroblasts, suggesting a role of lamin 
A/C maintaining a nucleoplasmic pool of 53BP1 (Gibbs-Seymour et al., 2015). 
Collectively, these studies illustrate a crucial role of lamin A/C in DNA repair.  
Given such physiological importance, mutations in lamin encoding genes may 
disrupt organism homeostasis and lead to pathological consequences. As a matter of 
fact, there are over 180 mutations in these genes that are associated with at least 13 
diseases (termed as the laminopathies), including HGPS (Capell and Collins, 2006). 
In HGPS, the presence of progerin disrupts the structure and function of the nuclear 
lamina and results in a variety of pathological phenotypes. At the systematic level, 
progerin induces severe premature aging phenotypes as described in 1.1. At the 
cellular level, progerin disrupts nuclear morphology, perturbs heterochromatin 
organization and interfere with numerous critical cellular processes such as DNA 
damage repair，mitochondrial respiration etc. (Capell and Collins, 2006; Dechat et 







1.3 HGPS cellular and molecular phenotypes 
 
1.3.1 Nuclear “blebbing” in HGPS 
Abnormal nuclear morphology is one of the most frequently observed 
phenotypes in HGPS. Primary fibroblasts from HGPS patients display a lobulated 
nuclear morphology termed as nuclear blebbing (Eriksson et al., 2003; Goldman et 
al., 2004). The abnormal nuclear shape is usually accompanied by a disrupted spatial 
distribution of nuclear pore complex (NPC) (Goldman et al., 2004). Interestingly, as 
progerin gradually builds up inside the cell, the “nuclear blebbing” phenotype 
becomes more severe, suggesting a role of progerin in this phenotypical development 
(Driscoll et al., 2012; Goldman et al., 2004). In fact, the farnesyl tail of progerin 
within the CAAX motif, enhances its affinity with SUN1, a component of the LINK 
(links the nucleoskeleton and cytoskeleton) complex, results in SUN1 accumulation 
at the nuclear envelope and potentially impacts nuclear structure (Chen et al., 2012; 
Chen et al., 2014). However, studies need to be done to further reveal the molecular 
and physical mechanisms underlying this phenotype.  
Structural abnormalities in the nucleus are often coupled with functional 
alterations. For example, NPC is a critical structure that spans across both inner and 
outer nuclear membranes and governs protein nuclear transportation (Kelley et al., 
2011). It is also a multi-functional apparatus that regulates a variety of other cellular 
processes including RNP assembly, mRNA quality control and SUMOylation (Kelley 
et al., 2011). Disruption of NPC organization in HGPS potentially impacts its 




cytoplasmic Ran gradient and impedes nuclear transportation of numerous proteins 
(Kelley et al., 2011; Zhang et al., 2014).  
 
1.3.2 Abnormal chromatin structure and epigenetic modifications in HGPS 
Progerin has been shown to interfere with chromatin organization in HGPS 
cells. Particularly, HGPS cells display a passage dependent progressive loss of 
peripheral heterochromatin, a highly organized and transcriptionally repressive 
chromatin structure that is mainly associated with nucleoli and nuclear lamina (Figure 
1-4). This loss is accompanied by progerin accumulation and nuclear lamina 
thickening (Goldman et al., 2004; McCord et al., 2013). Moreover, we have 
previously shown that there is a global loss of spatial chromatin compartmentalization 
in late passage HGPS cells by genome wide chromosome conformation capture (Hi-
C), suggesting additional structural abnormalities in HGPS (Goldman et al., 2004; 








Figure 1-4: Loss of peripheral heterochromatin in HGPS fibroblasts. Electronic microscopy analysis 
of HGPS fibroblasts at passage 18 and normal control fibroblasts (father of HGPS patient) at passage 
18, showing a loss of peripheral heterochromatin in HGPS nucleus. Regions cropped by dot boxes 
were illustrated by higher magnification views on the right. C and N indicate cytoplasm and nucleus 
respectively (adapted from McCord et al. Genome Res. 2013).  
 
Multiple lines of evidence have suggested abnormal histone modifications in 
HGPS cells (McCord et al., 2013; Scaffidi and Misteli, 2005; Shumaker et al., 2006). 
Specifically, progressive changes in histone methylations that mark heterochromatin 
were most frequently observed. These methylations are: facultative heterochromatin 
marker, trimethylation of histone H3 lysine 27 (H3K27me3) and constitutive 
heterochromatin markers, trimethylation of histone H3 lysine 9 (H3K9me3) and 
trimethylation of histone H4 lysine 20 (H4K20me3) (McCord et al., 2013; Shumaker 
et al., 2006). To date, H3K27me3 and H3K9me3 are found to be down-regulated in 
HGPS cells, while H4K20me3 has been shown to be down-regulated. These changes 
are not only observed in HGPS primary fibroblasts, but also seen in cells ectopically 
expressing progerin, suggesting a direct role of progerin in this abnormalities (Dechat 
et al., 2008). Significantly, the change in H3K27me3 happens as an early event, 
before the appearance of other cellular defects such as nuclear blebbing, and therefore 
is considered to be an upstream mechanism responsible for various cellular defects in 
HGPS (McCord et al., 2013; Shumaker et al., 2006). Indeed, our previous study 
illustrated that the association between lamin A/C and chromatin was reduced in 
regions with low H3K27me3 abundance in HGPS (McCord et al., 2013). 
Mechanistically, H3K27me3 was able to physically interact with lamin A/C. 




chromatin (McCord et al., 2013). These findings provided a mechanistic explanation 
of the heterochromatin loss phenotype in HGPS.  
Besides structural changes, abnormal epigenetic modifications also led to 
functional compromises in HGPS cells. For example, we have previously shown that 
local changes in H3K27me3 enrichment at specific gene promoters were significantly 
correlated with gene expression alterations in HGPS cells (McCord et al., 2013). Loss 
of H3K27me3 on the inactive X chromosome (Xi) results in partial decondensation of 
the X chromosome and can potentially cause transcriptional activation in those 
regions (Dechat et al., 2008; Shumaker et al., 2006). In addition to histone 
methylation, abnormal histone acetylation pattern is observed Zmpste24-/- mouse 
embryonic fibroblasts, a MEF that mimics HGPS by producing unprocessed prelamin 
A. Krishnan et al, reported that there was a down-regulation of acetylation on histone 
H4 lysine 16 in Zmpste24-/- MEFs. This down-regulation rendered a more condensed 
chromatin structure which created a physical barrier preventing DNA repair factors 
from access to the damaged DNA lesions (Krishnan et al., 2011).  
Over the past decade, scientists have revealed some mechanistic insights 
underlying these abnormal histone modifications in HGPS. For example, the loss of 
H3K27me3 is possibly due to a down-regulation of enhancer of zeste homolog 2 
(EZH2), a methyltransferase responsible for its maintenance (McCord et al., 2013; 
Shumaker et al., 2006). The mechanism that manifests H3K9me3 loss still remains to 
be uncovered. However, scientists reported a significant down-regulation of 
heterochromatin protein 1 (HP1), a histone binding protein that associated with 




2005; Xiong et al., 2015). Knockdown of HP1 results in a significant loss of 
H3K9me3, supporting the critical role of HP1 in H3K9me3 maintenance (Zhang et 
al., 2015). This information together highlights HP1 down-regulation as a potential 
candidate responsible for H3K9me3 loss in HGPS. 
  
1.3.3 Defective DNA damage repair and genome instability in HGPS 
As I discussed in 1.2.1, nuclear lamina serves as an important regulator in DNA 
damage repair. Deletion of lamin A/C leads to deficient DNA repair upon various 
types of DNA damages. Given such importance, functional disruption of the nuclear 
lamina by progerin may impact DNA damage repair and increase genome instability. 
Indeed, HGPS fibroblasts display a variety of phenotypes that can be caused by 
sustained DNA damage, such as reduced proliferative capacity, premature direct 
evidence demonstrating the defective DNA damage repair in HGPS was reported in 
2005. In that study, Liu et al. showed that upon the insult of excessive DNA damage 
by ionized irradiation, HGPS fibroblasts and Zmpste24-/- MEFs displayed a delayed 
recruitment of 53BP1, an important NHEJ regulator, towards the damaged DNA 
lesions (Liu et al., 2005). In addition, the recruitment of Rad51, a critical player in 
HR DNA damage repair pathway was also shown to be delayed in HGPS fibroblasts 
and Zmpste24-/- MEFs (Liu et al., 2005). As a result, HGPS fibroblasts or Zempste24-
/- MEFs displayed significantly higher sensitivity to DNA damage inducing agent and 
slower rate of recover compared to normal control (Liu et al., 2005). Notably over 




supporting a direct role of progerin impairing DNA damage repair (Manju et al., 
2006).  
Mechanistically, progerin was proposed to disrupt DNA damage repair by 
interfering with lamin A/C functionality. For example, Krishnan et al. reported that in 
Zmpste24-/- MEFs, unprocessed prelamin A interferes with the interaction between 
lamin A and the histone acetyltransferase Mof, disrupts Mof retention at nuclear 
matrix, and impairs 53BP1 foci formation at DNA lesions (Krishnan et al., 2011). In 
another study from the same group, unprocessed prelamin A and progerin was also 
shown to disrupt the interaction between lamin A and the NAD+-dependent 
deacetylase, Sirtuin 1 (SIRT1) (Liu et al., 2012). Given the importance of SIRT1 in 
DNA damage repair, this study points out a potential mechanism through which 
progerin impacts DNA damage repair. Epigenetic alterations are also proposed to 
impact DNA damage repair in HGPS or Zmpste24-/- cells. For example, loss of 
H4K16ac induced by prelamin A was considered to render a more condensed 
chromatin structure and create a physical barrier preventing DNA repair factors to 
access to the damaged foci in Zmpste24-/- MEFs (Krishnan et al., 2011). In addition, 
progerin was shown to reduce retinoblastoma binding protein 4 and 7 (RBBP4 & 
RBBP7) and histone deacetylase (HDAC), all of which were components of 
nucleosome remodeling deacetylase (NuRD) complex and played critical roles in 
chromatin modification. Importantly, loss of these proteins corresponded with DNA 
repair defects in HeLa cells, suggesting an alternative mechanism through which 





Not only, does progerin block DNA damage repair, its accumulation also 
increases the source of DNA damage. Specifically, it has been reported to induce 
DNA breaks by increasing the level of reactive oxygen species (ROS) (Richards et 
al., 2011; Xiong et al., 2015). It is well established that ROS is an important 
contributor to genome instability. By reacting with the double strand bonds, ROS is 
able to induce more than 20 types of DNA breaks (Cooke et al., 2003). If not properly 
repaired, single strand breaks (SSBs) created by ROS will turn into double strand 
breaks (DSBs) and threaten genome integrity. Importantly, it was previously reported 
that ROS accumulates in HGPS cells (Richards et al., 2011). Accumulated ROS was 
shown to correlate with impaired proliferation capacity in HGPS cells, in agreement 
with the inhibitory role of DNA damage in cell cycle progression (Richards et al., 
2011). Moreover, treatment with ROS scavenger N-acetyl cysteine (NAC) was able 
to alleviate their DNA damage basal level and improved population doubling times 
(Richards et al., 2011).  
Taken together, progerin jeopardizes genome integrity not only by disrupting 
proper DNA damage repair, but also by introducing more DNA damage. As a result, 
HGPS cells exhibit an elevated basal level of DNA damage (Liu et al., 2008). Un-
repaired DNA damage is proposed to be responsible for a variety of cellular defects in 
HGPS, including growth defects, premature senescence and genome instability 
(Krishnan et al., 2011; Liu et al., 2012; Liu et al., 2005; Liu et al., 2013a; Liu et al., 





1.3.4 Mitochondrial deficiencies in HGPS 
ROS production is highly correlated with mitochondrial functionality. 
Disruption of mitochondrial function could result in oxidative stress under various 
pathological situations (Murphy, 2009; Xiong et al., 2015). Studies performed by our 
group and others have confirmed a progerin induced mitochondrial disruption in 
HGPS cells (Rivera-Torres et al., 2013; Xiong et al., 2015).  To begin with, a recent 
SILAC (stable isotope labeling with amino acid) analysis revealed that the 
mitochondrial oxidative phosphorylation proteins were down-regulated in HGPS 
patients compared to normal subjects (Rivera-Torres et al., 2013). Similar reductions 
were also observed in fibroblasts obtained from adult progeroid mouse models: 
Zmpste24-/- and LmnaG609/G609 (a mouse progerin knock-in model) (Rivera-Torres et 
al., 2013). As expected, mitochondrial ATP synthesis was also found to be reduced 
HGPS fibroblasts (Pagano et al., 2014). Recently, our group showed that HGPS 
fibroblasts bear swollen and fragmented mitochondria (Xiong et al., 2015). 
Functional wise, HGPS fibroblasts and progerin expressing normal controls displayed 
slower mitochondria movement, disrupted mitochondrial membrane potential (MMP) 
and increased ROS (Xiong et al., 2015). Interestingly, HGPS cells displayed a 
significant down-regulation of the peroxisome proliferator-activated receptor gamma 
coactivator 1 (PGC1, a central regulator of mitochondrial biogenesis which 
controlled the expression of many mitochondrial proteins, suggesting a potential 
mechanism underlying mitochondrial deficiencies in HGPS (Xiong et al., 2015). 




directly inhibit PGC1 expression, validating a negative effect of progerin on 
mitochondrial structure and functionality (Xiong et al., 2015).  
 
1.3.5 Therapeutic approaches 
Based on HGPS pathology, several therapeutic approaches have been developed 
to either alleviate the toxic effects of progerin or reduce the amount of progerin. As I 
mentioned in 1.2.1, progerin retains a permanent farnesyl tail, resides on the inner 
nuclear membrane and disrupts nuclear structure. Therefore, one representative 
attempt to counteract progerin’s toxic effects is to block its farnesylation by using 
farnesyltransferase inhibitors (FTIs). Treating HGPS fibroblasts or normal fibroblasts 
over expressing progerin with FTIs was able to improve their nuclear morphologies 
(Capell et al., 2005). Moreover, in vivo studies on HGPS mouse models confirmed 
that FIT treatment was able to rescue a variety of disease phenotypes including 
growth retardation, bone sickness and vascular SMC loss (Capell et al., 2008; Yang et 
al., 2006). The positive results from these studies have led to a clinical trial of FTIs 
on HGPS patients (Gordon et al., 2012).  
Progerin has been shown to disrupt mitochondrial functionality, increase ROS 
and cause DNA damage (Rivera-Torres et al., 2013). Based on this information I 
proposed a novel approach to counter act progerin by targeting its defective 
mitochondria. Specifically, we adopted methylene blue (MB) a mitochondrial 
targeting antioxidant (Xiong et al., 2016). Our study showed that MB treatment not 
only rescued HGPS associated mitochondrial defects, but also significantly delayed 




and histone modifications (Xiong et al., 2016). Further analysis confirmed MB 
treatment drove a release of progerin from inner nuclear membrane. These results 
indicated MB as a promising therapeutic approach to treat HGPS. 
The second type of attempts aims at reducing the level of progerin and thereby 
reduce toxicities. For example, Scaffidi et al. were able to reduced progerin mRNA 
level by using sequence specific morpholino antisense oligonucleotides (AONs), 
which blocked the cryptic splicing sites. HGPS fibroblasts treated with AONs 
displayed improved nuclear morphology and fixed gene expression profile (Scaffidi 
and Misteli, 2005). In vivo study performed by Osorio et al. confirmed that 
morpholino treatment was able to alleviate disease phenotypes in an HGPS mouse 
model (lmnaG609G) (Osorio et al., 2011). However, the dosage of morpholino in these 
studies was relatively high (micromolar level). Therefore, attentions should be paid to 
off-target effects.  
Approaches have also been taken to directly reduce progerin protein level. In 
2011, Cao et al. showed that rapamycin, a macrolide antibiotic, was able to decrease 
the formation of insoluble progerin aggregates and stimulate progerin degradation by 
an autophagic mechanism in HGPS cells. In vitro study revealed that treatment with 
rapamycin was able to rescue HGPS nuclear morphology, delay cellular senescence 






1.4 Connections between HGPS and normal aging 
Whether progeriod disease such as HGPS resembles an accelerated form of 
normal aging is under debate for decades. Recent progresses on HGPS have identified 
phenotypical and mechanistic similarities between HGPS and normal aging process. 
For example, HGPS patients and conventional geriatric individuals share many 
common aspects in terms of cardiovascular pathology (Olive et al., 2010). 
Immunohistochemistry study on the artery of two HGPS patients who died from 
myocardial infarction identified a series of classical features that observed in normal 
aging atherosclerosis (Olive et al., 2010). In addition, several normal aging associated 
cellular phenotypes have been observed in HGPS including: cellular senescence, 
altered heterochromatin structure, defective DNA damage repair, disrupted 
mitochondrial function and etc., suggesting that there are common mechanisms 
shared between normal aging and HGPS (Burtner and Kennedy, 2010).  
The connection between HGPS and normal aging is strengthened by the 
discovery that progerin accumulates in normal senior individuals. Scaffidi et al. 
reported that primary cells from normal senior individuals displayed a sporadic use of 
the classic HGPS cryptic splice donor site, resulting in accumulation of progerin 
(Scaffidi and Misteli, 2006). Moreover, Olive et al. observed an age associated (1 
month to 97 years) progerin deposit that accumulates at a rate of 3.34% per year in 
the coronary arteries of normal individuals, suggesting that progerin may participate 
in normal cardiovascular pathology (Olive et al., 2010). Together, these evidences 




elucidating molecular mechanism underlying HGPS will benefit our understanding of 
normal aging processes. 
 
 
1.5 DNA damage responses (DDRs) 
 
1.5.1 DNA damage response, senescence, and aging 
Nuclear DNA is under constant attacks by endogenous or exogenous damaging 
inducing agents such as ROS, UV light, irradiation, chemical drugs etc. (Zhang et al., 
2014). These agents create multiple types of DNA damages including single strand 
DNA break (SSB), double strand DNA break (DSB), DNA inter-strand crosslinks 
(ICLs) etc. Among them, DSB is the most severe type of DNA damage, causing 
chromatin rearrangement, genome instability, cell death or cancer (Jackson, 2002). To 
properly handle DSBs, eukaryotic cells developed sophisticated mechanisms to sense 
and response to DSBs. Failure to properly fix DSBs will result in sustained DDR and 
form observable DDR foci, where DDR proteins are recruited to form aggregates and 
transduce DDR signals (d'Adda di Fagagna, 2008). Initial DDR signals at DNA break 
lesions are passed on to distant nuclear regions by diffusible checkpoint proteins such 
as CHK1 and CHK2. p53, then is activated and mediates cell cycle arrest by 
transcriptionally activating p21, a CDK inhibitor (d'Adda di Fagagna, 2008). This 
arrest is transient if DSBs are properly fixed. However, if DNA damage is severe, 
sustained DDR may induce a status of permanent cell cycle arrest termed cellular 




At the organism level, senescent cells are observed to accumulate within tissues. 
For example, senescence associated -galactosidase analysis revealed an increased 
percentage of senescent skin cells in aged healthy individuals (Dimri et al., 1995). A 
potential mechanism driving cellular senescence in vivo is through DDR activation. 
Indeed, DDR positive cells were observed more in the skin of baboons with age. 
These DDR foci (H2AX and 53BP1) were located at telomeric regions, suggesting 
telomere de-protection and replicative exhaustion during age (Herbig et al., 2006; 
Jeyapalan et al., 2007). The presence of senescent cells within tissues is considered to 
disrupt normal tissue homeostasis and contribute to physiological aging (Campisi, 
2001). Removal of p16 positive senescent cells from mice was shown to delay aging 
associated disorders (Baker et al., 2011).  
Given the role of DDR in cellular senescence, it is widely accepted that 
defective DNA damage repair causes accumulation of DSBs in HGPS cells and is 
responsible for their premature senescence phenotypes (Krishnan et al., 2011; Liu et 
al., 2005; Liu et al., 2013a; Liu et al., 2013b; Liu et al., 2008).  
 
1.5.2 Initiation and amplification of DDR signals upon DSBs 
DSBs can be directly recognized by proteins in a sequence independent manner 
(Polo and Jackson, 2011). For example, poly-(ADP-ribose) polymerase 1 and 2 
(PARP1 and PARP2) are among the most efficiently recruited proteins and severe as 
the sensor of DNA breaks (Polo and Jackson, 2011). They were shown to directly 
bind to DNA through their N terminal Zinc finger domain and basic N terminal 




binding will trigger their catalytic activity and mediate poly ADP-ribosylation at 
DNA breaks, initiating down-stream repair signals (Polo and Jackson, 2011). Other 
DNA break sensor proteins include Ku70-Ku80 complex and Mre11-Rad50-Nbs1 
(MRN) complex. Ku70-Ku80 complex binds to DSB break ends with high affinity 
and then recruits a variety of down-stream factors through protein-protein interaction 
(Polo and Jackson, 2011). Recognizing similar structures, Ku70-Ku80 complex and 
PAPR1 compete at DNA break ends to mediate different DNA repair programs (Polo 
and Jackson, 2011; Wang et al., 2006).  
After break detection, down-stream signaling proteins and repair factors are 
subsequently recruited to DSBs through protein-protein interaction with sensors. For 
example, DNA dependent protein kinase, catalytic subunit (DNA-PKcs) binds to the 
C terminus of Ku80 and is recruited to DSBs to mediate NHEJ (see next section) 
(Polo and Jackson, 2011). Another critical DDR signal protein is ataxia telangiectasia 
mutated (ATM). Through interacting with the MRN complex, ATM is recruited to 
DSBs, where it undergoes auto-phosphorylation and self-activation (d'Adda di 
Fagagna, 2008). Activated ATM, then phosphorylate histone variant H2AX at serine 
139, yielding H2AX, a modification widely viewed as a marker of DSBs (Bouquet et 
al., 2006; Burma et al., 2001; d'Adda di Fagagna, 2008). H2AX can be recognized 
by MDC1, whose join triggers the additional accumulation of MRN complex and 
ATM (d'Adda di Fagagna, 2008). Newly recruited ATM is able to phosphorylate 
adjacent H2AX and thereby create a positive feedback loop to amplify DDR signals 
(Bouquet et al., 2006; d'Adda di Fagagna, 2008; Polo and Jackson, 2011). In 




original broken DNA lesion (Polo and Jackson, 2011) (Rogakou et al., 1999). This 
process concentrates MDC1, which serves as a platform for the loading of various 
signal and repair factors such as 53BP1, RNF8, Nbs1, Rad51 etc (d'Adda di Fagagna, 
2008; Polo and Jackson, 2011).  
 
1.5.3 The error-prone NHEJ DSB repair pathway 
There are two major DSB repair pathways: non-homologous end joining 
(NHEJ) and homologous recombination (HR). NHEJ is the prevalent DSB repair 
pathway and is active throughout the cell cycle, although favored in G1 phase 
(Chapman et al., 2012). Unlike HR, which relays on the presence of sister chromatid 
as DNA template, NHEJ operates in a template independent manner. NHEJ mediates 
the direct ligation of two random DNA break ends at proximity and therefore is often 
error prone, resulting in small insertions or deletions of chromatin (Chapman et al., 
2012; Polo and Jackson, 2011). At the beginning of NHEJ, Ku70 and Ku80 form a 
ring-shaped heterodimer complex and encircles the duplex DNA ends with a strong 
equilibrium dissociation constant (~10-9 M) (Lieber, 2010; Polo and Jackson, 2011). 
Ku70-Ku80 complex serves as a dock to load additional kinase, nuclease and 
polymerases (Lieber, 2010). 
One of these factors is DNA-PKcs, a kinase that specifically binds to blunt end 
double strand DNA (Lieber, 2010). Once recruited, DNA-PKcs undergoes an initial 
auto-phosphorylation and acquires serine and threonine kinase activity (Lieber, 
2010). DNA-PKcs interacts, phosphorylates and activates with a variety of proteins, 




possesses 5’ exonuclease, 5’ endonuclease and 3’ endonuclease activities and is able 
to mediate break end resection on a wide range of DNA end configurations to create 
micro-homology (Lieber, 2010; Ma et al., 2002). However, this process is largely 
restricted, with a nucleolytic resection amount ranging from 0 to 14 nucleotides in 
most cases (Lieber, 2010).  
Polymerases  (Pol ) and  (Pol ) are directly recruited to Ku at DSBs 
through their BRCT domain (Lieber, 2010; Ma et al., 2004). Both Pol  and Pol  are 
much more flexible than most other polymerases during poly-nucleotide synthesis 
(Lieber, 2010). Pol  is particularly important for NHEJ as it mediates both template 
dependent and independent DNA synthesis (Gu et al., 2007; Lieber, 2010). Moreover, 
Pol  is able to incorporate rNTP into DNA strands which is important for NHEJ 
during G1 phase, when dNTP level is low and rNTP level is high (Gu et al., 2007; 
Lieber, 2010). Pol  is able to add random nucleotides to DNA blunt ends in a 
template independent fashion and create a 3’ single strand overhang, which will 
significantly enhance ligation efficiency (Lieber, 2010). However, due to this 
randomness, Pol  activity introduces heterogeneity during NHEJ even with a pair of 
relatively homogenous DNA ends to start with (Lieber, 2010). 
The final step of NHEJ is DNA ligation. DNA-PKcs is able activate the ligation 
activity of XRCC4-Ligase IV complex, which mediates the rejoining of two break 
ends (Lieber, 2010). Unlike other ligases, XRCC4-Ligase IV complex has very high 
enzymatic flexibility. It is capable of ligating complex DSB ends such as 
incompatible ends and nicking ends. In summary, enzymes (nuclease, polymerases 




different DNA conformations. These flexibility creates high mutation probability and 
therefore renders NHEJ as an error prone DSB repair pathway.  
 
1.5.4 The error-free HR DSB repair pathway 
As discussed above, NHEJ is favored in G1 phase although active during the 
entire cell cycle. In contrast, HR is mostly observed in S/G2 phase, when sister 
chromatid is accessible (Chapman et al., 2012; Mao et al., 2008; San Filippo et al., 
2008). Unlike NHEJ, which is error-prone, HR is mutation free and can accurately fix 
DSBs that arise from various sources including ionized irradiation, inter-strand cross 
linking, replication fork collapse (San Filippo et al., 2008). Particularly, HR but not 
NHEJ is capable of fixing replication fork collapse induced DSBs (San Filippo et al., 
2008). The necessity of HR in genome integrity maintenance is highlighted in two 
levels. At the cellular level, mutations in HR associated genes could result in 
hypersensitivity to DSB inducing agents such as ionized irradiation (Game and 
Mortimer, 1974; San Filippo et al., 2008). At organism level, heritable mutations 
associated with HR deficiency often lead to cancer or cancer prone diseases such as 
breast and ovarian cancers or Fanconi anemia and Bloom’s syndrome, (Kennedy and 
D'Andrea, 2006; Mathew, 2006; San Filippo et al., 2008; Sung and Klein, 2006).  
The substrate of HR machinery is single strand DNA (Sung and Klein, 2006). 
To achieve this, DSB ends (if blunt) have to be nucleolytically catalyzed to generate a 
3’ overhang in a process termed DNA end resection (Chapman et al., 2012). Unlike 
NHEJ, whose end resection is tightly restricted, the resection in HR tends to be more 




resection, the 3’-5’ endonuclease activity of Mre11 (a member of MRN complex) is 
required to create a nick on the DNA duplex at up to 300 nucleotides away from the 
break lesion (Chapman et al., 2012) (Figure 1-5). MRN complex then, proceeds to 
degrade DNA toward the 5’ break ends and dissociates Ku from DSB end (Chapman 
et al., 2012) (Figure 1-5). Meanwhile, the 5’-3’ endonuclease Exo1 is activated and 
mediate DNA degradation in the opposite direction as Mre11 (Chapman et al., 2012) 
(Figure 1-5).  
 
Figure 1-5: Model of MRN and CtIP dependent initiation of resection. (A). The Mre11 endonuclease 
within the MRN complex cleaves the 5’ strand at a distance that is far away (~300nt) from DSB ends. 
(B). DNA resection by MRE11 (3’ to 5’) and endonuclease Exo1 (5’ to 3’). (C). MRN complex 
counteracts Ku complex, releases Ku complex from DSB end and inhibits NHEJ. 
 
The resulting 3’ single strand DNA overhangs are quickly coated by replication 




and Jackson, 2011). In vertebrates, RPA is then substituted by Rad51, a eukaryotic 
Rec A homolog, with the help of other mediator proteins including, Rad51 paralogs 
(Rad51B, Rad51C, Rad51D, Xrcc2 and Xrcc3) and BRCA2 (Li and Heyer, 2008; 
Polo and Jackson, 2011).  The single strand DNA coated by Rad51 forms a structure 
termed nucleofilament. Rad51 together with other HR factors then mediate 
nucleofilament homology search and strand invading, a process when resected 
nucleofilament searches for and invades into the corresponding homologous template 
in the sister chromatid (Li and Heyer, 2008; Polo and Jackson, 2011). The invading 
strand anneals with its homologous template and drives off the original anti-sense 
strand forming a structure termed D loop (Li and Heyer, 2008). This anti-sense strand 
then forms duplex DNA with the second DNA break end either through annealing or  
a second invading event. Two break ends, together with sister chromatid forms an 
intermediate structure termed holiday junction (HJ) (Li and Heyer, 2008). HJ is then 
cleaved and resolved by enzymes to generate an intact error-free double strand DNA 
(Li and Heyer, 2008; Polo and Jackson, 2011). 
 
1.5.5 NHEJ vs. HR: a cell cycle-dependent regulation 
 NHEJ and HR are two antagonizing mechanisms that compete to repair DSBs. 
The key event that determines the choice between these two pathways is DSB end 
resection, which is restricted in NHEJ while more excessive in HR (Polo and Jackson, 
2011). DSB end resection is largely regulated by the interplay between two proteins: 
53BP1 and BRCA1, both of which are recruited to DSBs by DDR signals (see in 




inhibit HR and promote NHEJ, while BRCA1 does the opposite (Chapman et al., 
2012; Zimmermann et al., 2013). Loss of 53BP1 has been shown to extensively 
increase DSB end resection (Bothmer et al., 2011; Bunting et al., 2010). In addition, 
dominant negative 53BP1 mutant expression was reported to increase HR efficiency, 
confirming the negative role of 53BP1 on HR (Xie et al., 2007a). Mechanistically, 
53BP1 undergoes an ATM mediated phosphorylation and then recruits two additional 
effectors: RAP interacting factor 1 (RIF1) and PAX transactivation activation 
domain-interaction protein 1 (PTIP) (Panier and Boulton, 2014). Then 53BP1-RIF1 
complex binds to local H4 dimethylated on lysine 20 (H4K20me2) around DSBs to 
form a chromatin barrier and block resection machinery (Bothmer et al., 2010; 
Chapman et al., 2012). In addition to inhibiting DSB end resection, 53BP1 also 
promote NHEJ through its ability to increase DSB end mobility and tether distinct 
DSB ends to proximity for ligation (Chapman et al., 2012; Dimitrova et al., 2008).  
In a way to compete with NHEJ, HR adopts BRCA1 to promote DSB end 
resection. The exact mechanism underlying this BRCA1 mediated HR promotion 
remains unclear. However, multiple studies have revealed that depletion of 53BP1 is 
able to alleviate the detrimental phenotypes associated with BRCA1 deficiency in 
mouse models, suggesting that BRCA1 likely to promote HR by antagonizing with 
53BP1 (Bouwman et al., 2010; Bunting et al., 2012; Bunting et al., 2010; Cao et al., 
2009). 
As I mentioned before, HR is mostly active in S/G2 phase. Therefore, cells are 
likely to maintain a mechanism to reinstate HR and inhibit NHEJ during that period. 




during S/G2 phase (Chen et al., 2008). In addition, when cells enter S phase, cyclin 
dependent kinase (CDK) phosphorylates the CtBP interacting protein (CtIP), which in 
turn binds to BRCA1 and MRN complex to reinforce DSB end resection and 
antagonize 53BP1-RIF1 complex (Chapman et al., 2012; Escribano-Diaz et al., 2013; 
Panier and Boulton, 2014). Meanwhile, Lys acetyltransferase 5 (KAT5) carries out 
local histone acetylation events and generates histone H4 acetylated on lysine 16 
(H4K16ac), a marker that has been shown to reduce the binding between 53BP1 and 
H4K20me2 (Panier and Boulton, 2014; Tang et al., 2013).  
Proper regulation of NHEJ and HR pathway choice is critical for cells to 
maintain homeostasis. Disruption of this process could result in chromatin relocation, 
genome instability and cell death. For example, PARP1 inhibitors are lethal on 
BRCA1 deficient cells by introducing excessive DSBs and inappropriately activating 
the error-prone NHEJ, leading to chromatin aberrations and cell death (Bunting et al., 
2010; Patel et al., 2011). Deletion of 53BP1 inhibits NHEJ, restores HR and 
completely removes the toxicity of PARP inhibitors, suggesting a toxic effect of 
NHEJ on genome integrity (Bunting et al., 2010).  
 
1.5.6 Impact of H2AX signals on NHEJ and HR 
As discussed in 1.4.2, ATM mediated H2AX phosphorylation plays a central 
role coordinating DDR signal amplification (Chapman et al., 2012; Kinner et al., 
2008). The major significance of H2AX is its ability to attract down-stream DNA 
repair factors through direct or indirect mechanisms (Chapman et al., 2012; Kinner et 




tail on H2AX through its BRCT domain repeats. The enrichment of MDC1 recruits 
MRN complex and ATM at DSBs. ATM phosphorylates MDC1, initiating further 
recruitment of RNF8 and RNF168, two E3 ubiquitin ligases (Kinner et al., 2008; 
Kolas et al., 2007). With the help from E2 conjugating enzyme UBC13, 
RNF8/RNF168 mediate the poly-ubiquitination of histone H2A and H2AX, which 
reinforce the efficient and stable recruitment of 53BP1 and BRCA1 (Fradet-Turcotte 
et al., 2013; Kolas et al., 2007; Mailand et al., 2007). Therefore, H2AX serves as 
upstream signals to promote NHEJ and HR. Notably, the association equilibrium 
between MDC1 and H2AX are relatively low (~10-6 M). Therefore, a widespread of 
H2AX signals is likely to help stabilize the DDR machinery at DSBs. Depletion of 
H2AX has been shown to disrupt 53BP1 recruitment (Ward et al., 2003). To this end, 
it is proposed that H2AX dependent 53BP1 recruitment functions to block DSB end 
resection during class-switch recombination in immune cells (Chapman et al., 2012; 
Reina-San-Martin et al., 2004). Besides 53BP1, depletion of H2AX was also shown 
to impede BRCA1 and RAD51 recruitments (Bassing et al., 2002; Paull et al., 2000). 
Mouse embryonic stem cells lacking H2AX displayed elevated genome instability 
and sensitivity to ionized irradiation (Bassing et al., 2002). 
 
1.6 Significance of this dissertation 
As discussed in 1.1.3, vascular smooth muscle cell loss is a drastic phenotype 
observed in HGPS patient and mouse models. Moreover, this phenotype has been 
implied to be associated with cardiovascular disorders, the driving force of HGPS 




mechanism underlying this phenotype of SMC loss in HGPS. In chapter II, I begin by 
establishing a differentiation protocol to generate HGPS SMCs via induced 
pluripotent stem cells (iPSCs). I fully characterize these cells and provide the first 
evidence that HGPS SMCs undergo elevated basal level cell death. In chapter III, I 
aim to illustrate the mechanism of HGPS SMC cell death. PARP1 is shown to be 
significantly down-regulated in the HR deficient HGPS SMCs, resulting in over-
activation of NHEJ during S/G2 phase, leading to chromosome aberrations and 
mitotic catastrophe. Chapter IV characterizes the efficiencies of both HR and NHEJ 
at different cell cycle stages in HGPS fibroblasts. Microscopy analysis reveals that 
both HR and NHEJ are abnormally regulated in G0/G1 phase or S/G2 phase HGPS 
fibroblasts. This is the first cell cycle dependent analysis of NHEJ and HR in HGPS 
cells. Chapter V focuses on investigating the molecular mechanism underlying NHEJ 
mis-regulation. I provide evidence showing that ATM activity and H2AX 
phosphorylation are differentially regulated between G0/G1 phase and S/G2 phase 
HGPS cells. The disruption of these upstream DDR signals is associated with mis-
regulated NHEJ. Moreover, my data suggests that loss of H3K9me3 in HGPS cells 
plays a role in these defects. Together, my study demonstrates an attenuated early 
DDR signal of ATM activation and H2AX phosphorylation and provides a plausible 
connection between the classic H3K9me3 loss phenotype and mis-regulated NHEJ in 

















Chapter II: Differentiation and characterization of HGPS 














Hutchinson-Gilford progeria syndrome (HGPS), the most drastic form of 
premature aging diseases, is characterized by multiple aging-related clinical features 
including growth retardation, lipodystrophy, alopecia, bone abnormalities and severe 
cardiovascular defects (Capell and Collins, 2006; Merideth et al., 2008). Patients with 
HGPS typically start to display premature onset of aging-related pathologies at 12-24 
month of age and die in their early teens of heart attacks or strokes (Capell and 
Collins, 2006; Merideth et al., 2008). Over 80% HGPS cases are caused by a de novo 
mutation (1824 C→T) in exon 11 of the human LMNA gene. This mutation activates 
an alternative splice donor site, leading to a truncated lamin A mutant termed 
“progerin”, which bears a 50 aa deletion near the C terminus (Capell and Collins, 
2006). This internal deletion interferes with lamin A processing and causes a 
permanent farnesylation of progerin. As a dominant negative protein, the 
accumulation of progerin inside the nucleus causes various cell biological phenotypes 
including a misshapen nuclear morphology, loss of peripheral heterochromatin, 
global changes in gene transcription and disrupted mitotic progress (Capell and 
Collins, 2006; Zhang et al., 2013).  
Among all of the clinical features associated with HGPS, the cardiovascular 
disease is the cause of death in almost all patients. Despite its great importance, 
investigation of the HGPS arterial pathology has been extremely limited mainly due 
to the low incidence of HGPS. One postmortem study on an HGPS patient found a 
severe loss of SMCs in the aorta and carotid arteries (Atkins, 1954). Moreover, two 




LmnaG609G models, respectively) confirmed the loss of SMCs in large vessels (Osorio 
et al., 2011; Varga et al., 2006). Significantly, this SMC loss could be largely rescued 
by treating the mice with farnesyltransferase inhibitors (FTIs) or progerin suppressing 
morpholinos, indicating a causal connection between the presence of progerin and the 
SMC loss phenotype (Capell et al., 2008; Osorio et al., 2011). Loss of vascular SMCs 
(aortic arch and carotid arteries) has been proposed to induce aortic dilation and 
atherosclerosis plaque rupture (Bennett, 1999; Clarke et al., 2006). Thus elucidating 
the molecular mechanism underlying HGPS SMC loss is of great importance to 
understand the cardiovascular pathology and develop new therapeutic approaches in 
HGPS. 
To investigate how progerin induces cell death in HGPS SMCs, in vitro culture 
of primary SMCs from HGPS patients is an ideal system. However, there are several 
challenges hurdling this strategy. First of all, HGPS is an extremely rare disease with 
an incidence rate of one in every four to eight million of population (Capell and 
Collins, 2006; Zhang et al., 2013). It is difficult to find the source of HGPS primary 
SMCs. Secondly, dissection of SMCs from in vivo large vessels is impractical 
compared with other cell types such as dermal fibroblasts. In recent years, with the 
emerge of induced pluripotent stem cells (iPSCs), there is an increasing interest in 
using iPSCs as a new source to study specific diseases. With pluripotency, iPSCs are 
able to differentiate into multiple lineages including SMC. Therefore, in this chapter, 
I developed a lineage specific differentiation protocol and generated HGPS SMCs 
from HGPS iPSCs. Physiological examinations suggested that HGPS SMC exhibit 




molecular analysis suggested that HGPS SMCs faithfully recapitulated classic HGPS 
cellular phenotypes such as premature senescence and proliferation defects. 
Significantly, HGPS SMCs displayed a drastically elevated basal level of cell death, 





2.2.1 Normal and HGPS iPSC show comparable differentiation potency into 
SMC lineage. 
To study HGPS SMC defects, SMCs were generated from iPSCs derived from 
HGPS and normal skin fibroblasts. Analysis of HGPS iPSCs revealed the expression 
of Oct4, Nanog, SSEA4 and Tra1-60, indicating that these HGPS iPSCs contain 
essential pluripotency factors, as well as normal chromosome number and size 
(Figure 2-1A-C). Alkaline phosphatase (AP) staining and EB formation assay further 
demonstrated the undifferentiated state and the differentiation potential of iPSCs 
(Figure 2-1A-E). In accordance with previous reports, the expression of lamin A/C 












Figure 2-1: Characterization of HGPS iPSCs. (A). Representative images of phase contrast, alkaline 
phosphatase (AP) staining, and pluripotency marker immunofluorescence staining of normal and 
HGPS iPSC colonies. (Scale bar, 200 μm) (B). RT-PCR with denoted pluripotency gene primers in the 
samples of normal and HGPS iPSCs and the parent fibroblasts (Fibs). PCR products of each indicated 
gene in various samples were run together on a single gel. Representative normal and HGPS samples 
were cropped and aligned together, separated by white lines. (C). Normal karyotypes of normal and 
HGPS iPS colonies. (D). Representative images of immunofluorescence staining with anti-lamin A/C 
and anti-lamin B antibodies on normal and HGPS iPSC colonies. DNA was stained by Hoechst 33342. 
(Scale bar, 200 μm.) (E). Representative images of immunofluorescence staining with anti–β-tubulin, 
Vimentin and α-fetoprotein (AFP) antibodies on normal and HGPS EBs. Immunofluorescence signal 
of β-tubulin, vimentin, and AFP confirmed the differentiation of ectodermal, mesodermal, and 








Figure 2-2: Schematic diagram of SMC differentiation timeline and representative phase contrast 
images underneath each denoted stage. EB, embryoid body. (Scale bar, 400 μm.)  
 
SMCs were differentiated from iPSCs using a previously established protocol 
(Figure 2-2, see details in Methods) (Xie et al., 2007b). After 7 d in the SMC 
differentiation medium, immunofluorescence revealed the expression of SMC-
specific markers SMC--actin (SMA) and calponin in both normal and HGPS lines 
(Figure 2-3A). In accordance with the immunofluorescence observation, Western 
blotting analysis and RT-quantitative PCR (RT-qPCR) showed a significant up-
regulation of SMA, calponin and SM22-a in SMCs relative to iPSCs, fibroblasts and 
pre-SMCs (Figure 2-3B & C and 2-4A). Notably, the expression of smooth muscle 
myosin heavy chain (smMHC), a marker for terminally differentiated SMCs, was not 
up-regulated in normal and HGPS SMCs, suggesting that SMCs in my system were 
not terminally differentiated (Figure 2-3B). FACS analysis using fluorescence-labeled 
SMA or calponin revealed that, after 14 d in SMC differentiation medium, >80% of 
the cells were induced to express SMA and calponin (Figure 2-4B). Western blotting 
analysis suggested that the expression of these SMC markers was stable for at least 




Next, I carried out contractility analysis on normal and HGPS SMCs. Cells at day 14 
and 21 were treated with a vasoconstrictor, angiotensin II. More than 70% of the 
SMCs displayed various levels of contraction 30min after stimulation (Figure 2-4C & 
D). Taken together, these results indicated that both normal and HGPS iPSCs were 





Figure 2-3: Expression of SMA and calponin in normal and HGPS SMCs. (A). Representative images 
of immunofluorescence staining with anti-SMA and anti-calponin antibodies on normal and HGPS 
SMCs. (Scale bar, 50 μm.) (B). RT-qPCR with SMA, calponin, smMHC, and SM22-α–specific 
primers on normal and HGPS iPSCs, pre-SMCs, and SMCs. ***P < 0.001. (C). Western blot with anti-









Figure 2-4: Normal and HGPS SMCs express SMC markers. (A). Western blot with anti-SMA, 
calponin, and GAPDH antibodies on the cell samples at various differentiation stages. (B). Percentages 
of SMA and calponin positive population in normal and HGPS SMCs at day 14. Results were 
generated from two biological replicates. (C). Representative phase control images showing the 
contraction of normal and HGPS SMCs at days 14 and 21 upon angiotensin II treatment. Cell 




400 μm.) (D). Quantification of C, showing the percentage of contracted SMCs upon stimulation. 
Results were generated from three independent experiments. 
 
To measure progerin amounts during SMC differentiation, western blotting 
analysis and immunofluorescence were conducted and revealed a gradual 
accumulation of progerin in HGPS cells during SMC differentiation (Figure 2-5A-C). 
Senescence-associated -galactosidase (SA--gal) staining suggested that HGPS 
SMCs were more senescent than normal SMCs at similar stages (Figure 2-6A). 
Interestingly, p16ink4a, a senescence marker and cyclin-dependent kinase inhibitor, 
was found to be up-regulated in HGPS SMCs relative to the normal controls (Figure 
2-6B & C) (Baker et al., 2011). Next, I examined whether the senescence in HGPS 
SMCs was related to shortened telomeres in HGPS, as suggested previously (Liu et 
al., 2011). RT-PCR using a pair of human telomerase reverse transcriptase (hTERT)-
specific primers revealed that hTERET was robustly expressed in iPSCs but 
undetectable in both normal and HGPS SMCs (Figure 2-6D), indicating that 
telomerase expression was significantly inhibited upon SMC differentiation. Using 
quantitative telomere PNA-FISH, as described before by Cao et al (Cao et al., 2011a), 
I found no evidence of shortened telomeres in HGPS SMCs as well as in primary 
vascular SMCs isolated from G608G transgenic mice, in which the SMC loss was 














Figure 2-5: Expression of progerin in HGPS SMCs. (A). Western blot with anti-lamin A/C and anti-
GAPDH antibodies on normal and HGPS SMCs at indicated time points during differentiation. Lamins 
A and C were detected in all SMC samples, and progerin was only observed in HGPS SMCs. (B). 
Quantification of A, showing gradual increases of progerin in HGPS SMCs with culturing time. 
Results were generated from two independent experiments. (C). Representative images of 
immunofluorescence staining with anti-lamin A/C and progerin antibodies on normal and HGPS SMCs 






Figure 2-6: Premature senescence in HGPS SMCs. (A). Representative images of SA–β-Gal staining 
on normal and HGPS SMCs at indicated time points during differentiation. (Scale bar, 200 μm.) (B). 
Western blot with anti-p16ink4a and GAPDH antibodies on normal and HGPS SMCs at indicated time 
points during differentiation. (C). RT-qPCR with p16ink4a-specific primers on normal and HGPS 
SMCs at indicated time points during differentiation. **P < 0.01, ***P < 0.001. (D). RT-PCR with 
human TERT and GAPDH-specific primers on normal and HGPS iPSCs and SMCs. The expression of 
TERT was undetectable by RT-PCR in normal and HGPS SMCs. SMC samples at various time points 
were run separately and are denoted by white lines. (E). Representative images of telomere PNA-FISH 
staining. (F). Quantification of telomere PNA-FISH fluorescence intensity in the indicated cell types. 
The HGPS (G608G) and control (nontransgenic, NT) mouse samples were age, sex, and passage 
matched. In both differentiated human SMCs and primary mouse vascular SMCs, HGPS samples 
showed slightly but significantly stronger PNA-FISH signals (***P < 0.001). I found no evidence of 




2.2.2 HGPS SMCs exhibit proliferation defects and elevated basal level of cell 
death. 
To evaluate cell proliferation potential, growth curves were plotted for HGPS 
and normal SMCs (Figure 2-7A & B). This experiment showed that, where as normal 
SMC kept a constant proliferation rate, the cell number of HGPS SMCs stopped 
increasing after day 14. I reasoned that this proliferative defect could be caused by 
either premature senescence or progerin induced cell death. To distinguish these two 
possibilities, I conducted a cell cycle analysis at day 14. If premature senescence of 
HGPS SMCs was the dominant cause, the majority of HGPS SMCs should be  
arrested in the G0/G1 phase of the cell cycle. To my surprise, cell cycle analysis 
revealed that the percentage of the G0/G1 population of HGPS SMCs showed no 
significant changes compared with the control (~70% in both), but there was an 
obvious increase in the mitotic population (G2/M) in HGPS SMCs (Figure 2-7C). 
This result suggested that despite being more senescent than normal SMCs, HGPS 
SMCs did not lose their proliferative ability. Thus, I speculated that the proliferation 
defect in HGPS SMCs was likely caused by cell death occurring during cell division. 
To analyze cell death, next, I carried out propidium iodide (PI)-annexin V assay 
in both normal and HGPS SMCs at weekly time points during SMC differentiation. 
Indeed, HGPS-SMCs displayed 8- to 10- fold increase in cell death compared with 
normal controls at days 14, 21 and 28 (Figure 2-7D & E). Notably, at the early time 
point day 7, when no obvious growth defect was detected (Figure 2-7B), both normal 
and HGPS SMCs showed a similar percentage of cell death, implying a relatively 




E). These results strongly supported my speculation that the proliferation defect in 
HGPS SMCs was caused by cell death. Furthermore, these results provide a plausible 
explanation for the in vivo SMC loss phenotype in HGPS.   
 
Figure 2-7: Increased cell death in HGPS SMCs. (A) Growth curve of normal and HGPS SMCs 
during differentiation. Results were generated from three biological replicates. *P < 0.05, **P < 0.01. 
Blue and green arrows referred to the images at days 7 and 21 in B, respectively. (B) Representative 
phase contrast images of normal and HGPS SMCs at days 7 and 21 during SMC differentiation. (Scale 
bar, 200 μm.) (C) Cell cycle analysis of normal and HGPS SMCs at day 14, illustrating the distribution 
of G0/G1, S, and G2/M phases. Results were generated from three biological replicates. *P < 0.05. (D) 
PIannexin V flow cytometry analysis on normal and HGPS SMCs at various time points during SMC 
differentiation. The gates were set according to the positive and negative controls as suggested by the 
manufacturer. The cells in the Lower Right quadrant were scored as the dying cell population. (E) 
Quantification of D, showing the percentage of dying population based on the PI-annexin V assay. 
Results were generated from three biological replicates. *P < 0.05, **P < 0.01. (F) RT-qPCR analysis 








2.3.1 iPSCs based SMC differentiation model 
Children with progeria die almost exclusively from cardiovascular disease. In 
2006, Varga et al. reported the first evidence of progressive vascular SMC loss in 
large vessels of an HGPS transgenic mouse model (G608G BAC) (Varga et al., 
2006). SMC loss might undermine vessel architecture and induce inflammation, 
vessel calcification, and excessive atherosclerosis (Lopez-Candales et al., 1997). The 
mechanisms underlying progerin-induced SMC loss had not been explored, which 
was at least partially due to the technical difficulties in obtaining sufficient amounts 
of vascular SMCs from progeria patients or animal models.  
In this chapter, the problem was overcome by the iPSCs-mediated 
differentiation system that generated a large amount of patient SMCs. I found that 
these differentiated cells were induced to express some established SMC markers and 
exhibited functional characteristics of SMCs (Figure 2-3 and Figure 2-4). However, 
the expression of smMHC, a marker for fully differentiated SMCs, was undetectable 
(Figure 2-3B), which suggested that the SMCs in my experiments were not terminally 
differentiated. Indeed, the proliferation assay (Figure 2-7A & B) showed that the 
normal SMCs could proliferate in SMC differentiation medium for at least 28 days. In 
vivo, SMC proliferation is a characteristic of synthetic SMCs, and contractile SMCs 
do not proliferate (Rensen et al., 2007; Rzucidlo et al., 2007). Under pathological 
conditions, SMCs switch from the contractile to the synthetic phenotype (Rensen et 




SMCs, I may be studying how progerin affects SMCs responses to pathological 
conditions in vivo. 
 
2.3.2 The proliferative defect in HGPS SMCs is primarily caused by cell death, 
not by premature senescence. 
The HGPS SMCs expressed progerin, a hallmark of HGPS cells (Figure 8), and 
stopped proliferating after two weeks in SMC culture (Figure 2-7A & B). Initially, I 
had hypothesized that this severe growth defect was caused by premature senescence, 
as previously suggested by Liu and colleagues and supported by my senescence 
analysis with SA–β-Gal assay and p16 expression (Figure 2-6A-C) (Liu et al., 2011). 
However, to my surprise, cell cycle analysis indicated that the HGPS SMCs did not 
rest at G0, but actively reentered the cell cycle (Figure 2-7C). Moreover, I found a 
significant delay in G2/M phase in the HGPS SMCs (Figure 2-7C). Additional 
experiments revealed a time-dependent increment of cell death in HGPS SMCs in 
culture (Figure 2-7D & E). Based on these results, I concluded that the cell death 





















Chapter III: Mechanisms controlling the smooth muscle cell 
















DNA damage often arises as a result of normal cellular processes. Reactive 
oxygen species (ROS), the byproducts of cellular metabolism, can damage DNA 
bases and block the progression of replication, leading to replication fork collapse and 
double-strand breaks (DSBs). DSBs can also be induced by environmental factors 
including irradiation, chemical agents, or UV light (Rothkamm et al., 2003). A 
gradual accumulation of DSBs and a decline in DNA repair capacity are suggested to 
play a causative role in normal physiological aging (Chen et al., 2007). Defects in 
DNA damage repair result in at least three premature aging diseases: xeroderma 
pigmentosum, Cockayne syndrome, and trichothiodystrophy (Kraemer et al., 2007). 
In addition, impaired DNA repair has also been implicated in the development of age-
related neurodegenerative diseases such as Alzheimer’s disease, Parkinson disease, 
and Huntington disease (Lin and Beal, 2006).  
At the cellular level, DSBs are potent inducer of cell death, if left unrepaired, 
DSBs can trigger p53-mediated cell cycle arrest and programmed cell death; on the 
other hand, if repaired inaccurately, DSBs can cause small or large scale chromosome 
alterations, which can lead to premature entry into mitosis and mitotic cell death 
(mitotic catastrophe) (Vakifahmetoglu et al., 2008). Two separate pathways control 
the repair of DSBs: homologous recombination (HR) and non-homologous end 
joining (NHEJ). HR repairs DSBs using the undamaged sister chromatid as a 
template, during S/G2 phase and effectively protects genome integrity. In contrast, 
NHEJ repairs DSBs by connecting two free chromosome ends together with litter 




mis-arrangements (Rothkamm et al., 2003). Normally these two pathways antagonize 
each other to fix DSBs and the choice between these two is under precise control by a 
group of regulators including 53BP1, BRCA1 and poly(ADP-ribose) polymerase 1 
(PARP1) (Bunting et al., 2010; Patel et al., 2011).  
Among these regulators, PARP1 acts as an essential molecular switch 
controlling activities of HR and NHEJ pathways. The classic function of PARP1 is 
involved in sensing initiating DNA single-strand break (SSB) repair (Caldecott, 
2008). A previous study demonstrated that treating an HR-deficient cell line with a 
PARP1 inhibitor led to abnormal chromosome karyotypes and significantly reduced 
cell survival, suggesting that PARP1 mediates the suppression of NHEJ upon DSBs 
(Bunting et al., 2010). This sensitivity to a PARP1 inhibitor in the HR-deficient cells 
could be a combined effect of the PARP1’s dual roles in DNA damage repair. First, 
inhibition of PARP1 hinders SSB repair and the unrepaired SSBs develop into DSBs. 
More importantly, inhibition of PARP1 removes the suppression of NHEJ which 
results in chromosome aberrations and subsequent cell death in these HR-deficient 
cells (Bunting et al., 2010).  
Depletion of smooth muscle cells from the major vessels is a frequently 
observed phenotype in HGPS patients and animal models (Atkins, 1954; Osorio et al., 
2011; Varga et al., 2006). It has been previously shown that vascular SMC loss plays 
a positive role in the development of cardiovascular disorders such as aortic dilation 
and atherosclerosis, making it an interesting target to understand the cardiovascular 
pathology in HGPS (Bennett, 1999; Clarke et al., 2006). To model this phenotype, I 




(see Chapter II). HGPS SMCs displayed classic HGPS cellular phenotypes such as 
proliferation defects and premature senescence. More importantly, HGPS SMCs bear 
an elevated basal level of cell death, suggesting a plausible cellular mechanism to 
explain the in vivo SMC loss. However, the molecular mechanism underlying this 
HGPS SMC cell death phenotype remains largely unknown. 
In this chapter, I aim to investigate how progerin accumulation induces cell 
death in HGPS SMCs. Insightfully, deficiencies in DNA damage repair have been 
reported in HGPS fibroblasts and various progeria animal models, suggesting a likely 
involvement of genome instability in the manifestation of this drastic premature aging 
disease (Krishnan et al., 2011; Liu et al., 2005; Liu et al., 2013a; Liu et al., 2013b; 
Osorio et al., 2011). More specifically, HR DSB repair pathway has been shown to be 
impaired in HGPS fibroblasts, allowing us to speculate a similar HR deficiency in 
HGPS SMCs (Liu et al., 2005).  
Here I present data showing that HR activity was almost completely blocked in 
HGPS SMCs during S/G2 phase. Moreover, I demonstrate that the accumulation of 
progerin directly down-regulates PARP1. Consistent with previous reports that 
PARP1 inhibition was lethal to HR deficient cells (Bunting et al., 2010; Patel et al., 
2011), down-regulation of PARP1 by progerin in the HR deficient HGPS SMCs 
stimulated the error-prone NHEJ responses in S/G2 phase. Consequently, HGPS 
SMCs encounter chromosome aberrations and cell division problems and die in 








3.2.1 HGPS SMCs underwent caspase 3 independent cell death 
Previously, I have shown that HGPS SMCs bear an elevated basal level of cell 
death using PI-annexin V assay, which has been frequently applied in apoptosis study 
(Figure 2-7D & E). I next wondered whether HGPS SMCs death was caused by 
classic apoptosis pathway. To test this, I measured the mRNA level of Bcl2-
associated protein X (Bax), a major proapoptotic gene acting upstream of caspase 
(Oltvai et al., 1993). Interestingly, no significant change in Bax expression was 
observed in HGPS SMCs compared with the normal control (Figure 3-1A), implying 
that caspase was not activated in HGPS SMCs. To further investigate this, I checked 
the activity of caspase 3. Activity assay revealed that caspase 3 was not activated but 
slightly suppressed in HGPS SMCs (Figure 3-1B). Consistently, I did not detect any 
cleaved PARP1 protein, a well-known substrate of caspases, in either sample (Figure 
3-1C). Moreover, I did not find any obvious sub-G1 population in HGPS SMCs, 
indicating that there was no DNA fragmentation (Figure 3-1D). Taken together, these 
data suggested that cell death in HGPS SMCs may be executed in a caspase-
independent manner.  
It has been shown that treatment with high dosages (micro molar) camptothecin 
(CPT), a topoisomerase I inhibitor, can induce caspase-dependent apoptosis in normal 
cells (Ulukan and Swaan, 2002). Thus, as a positive control to the above experiments, 
I treated both normal and HGPS SMCs with 20mM CPT. In control SMCs, I detected 




folds after 72h in CPT treatment (Figure 3-1E & F). Consistently, cleaved PARP1 
was clearly detected by western blotting in these cells (Figure 3-1G). However, 
HGPS SMCs appeared quite unresponsive to CPT induction, which failed to activate 
Bax expression and exhibited a delay over 48h in caspase 3 activation and PARP1 
cleavage (Figure 3-1E-G). PI-annexin V assay further confirmed no significant 
increase in cell death in HGPS SMCs after CPT treatment (Figure 3-1H). These 
results suggest that, in the presence of progerin, caspase become less responsive to 
apoptotic stimuli like CPT. Collectively, I concluded that progerin accumulation in 





Figure 3-1: HGPS SMC cell death is caspase 3 independent. (A). RT-qPCR analysis with Bax specific 
primers on normal and HGPS SMCs at different time points during SMC differentiation. (B) Basal 
caspase 3 activity of normal and HGPS SMCs at day 14. Results were generated from two independent 
biological replicates. (C). Western blot with anti-PARP1 and GAPDH antibodies on normal and HGPS 
SMCs at indicated time points during differentiation. (D). Percentage of the sub-G1 population in 
normal and HGPS SMCs at days 14, 21, and 28. (E). RT-qPCR with Bax-specific primers on normal 
and HGPS SMCs after treatment with 20 μM CPT for the indicated period, respectively. **P < 0.01, 
***P < 0.001. (F). Caspase 3 activity assay on normal and HGPS SMCs after treatment with 20 Μm 
CPT for the indicated period, respectively. (G). Western blot with anti-PARP1 and GAPDH antibodies 
on normal and HGPS SMCs after treatment with 20 μMCPT for the indicated period, respectively. (H). 
Representative plot of PI-annexin V FACS analysis on normal and HGPS SMCs after 24-h treatment 
with 20 μM CPT. 
 
3.2.2 Progerin accumulation down-regulates PARP1 in HGPS SMCs 
When probing PARP1 cleavage in the caspase studies, I observed that the levels 
of PARP1 protein were always lower in HGPS SMCs compared to the normal 
controls at days 14, 21 and 28 (Figure 3-1C & G), whereas no obvious changes were 
detected at day 7 (Figure 3-2A). To confirm this observation, I measured PARP1 
levels in two different HGPS SMC lines at day 14 and found that the PARP1 levels in 
both were decreased by at least 75% relative to the control (Figure 3-2B). 
Immunofluorescence showed a significant decrease in PARP1 nuclear staining in 
HGPS SMCs at day 14 compared with the normal control (Figure 3-2C & D). 
Moreover, in primary skin fibroblasts from HGPS patients and a transgenic animal 
model G608G (Varga et al., 2006), similar PARP1 reduction was found in late 
passage cells (Figure 15 A & B). Resembling the cell cycle analysis in HGPS SMCs 
(Figure 2-7C), a significant increase in the G2/M population was detected in late 
passage HGPS fibroblasts (Figure 3-3C-F). Notably, there was no significant change 




to the day 7 HGPS SMCs (Figure 3-2A). This suggests that the PARP1 reduction 
phenotype is not exclusive for SMCs, but a consequence of progerin accumulation in 
each cell type. As an initial executor of SSB repair and a key mediator of DNA DSB 
repair, PARP1 plays a crucial role in maintaining genome stability. Thus, I next 
examined whether PARP1 reduction was relative to increased cell death in progerin 
expressing SMCs.  
 
Figure 3-2: PARP1 is down-regulated in HGPS SMCs. (A). Western blot with anti-PARP1 and 
GAPDH antibodies on normal and HGPS SMCs at day 7 during SMC differentiation. (B, Upper) 
Western blot with anti-PARP1 and GAPDH antibodies on two HGPS SMC lines (HGADFN167 and 
HGADFN164) and a normal control SMC line at day 14. (Lower) Quantification of PARP1 in each 
sample. The intensity of PARP1 was first normalized to the corresponding GAPDH and then 




PAPR1 antibody in normal and HGPS SMCs at day 14. (Scale bar, 50 μm.) (D). Quantification of B, 








Figure 3-3: PARP1 is down-regulated in HGPS fibroblasts and BACG608G MEFs. (A). Western blot 
with anti-PARP1 and GAPDH antibodies on normal and HGPS fibroblasts at early (passages 14 and 
12) and late (passage 19) cellular stages. (B). Quantification of A. Data was first normalized to loading 
control GAPDH, then to the early passage normal fibroblast. Results were generated from three 
independent experiments. ***P < 0.001. (C) Western blot with anti-mouse PARP1, lamin A/C, and 
HDJ2 antibodies on nontransgenic (NT) or G608G transgenic mouse fibroblast samples. Two mice 
were included for each genotype. (D) Quantification of D. Data were first normalized to loading 
control GAPDH, then to WT mouse 1. Results were generated from at least three independent 
experiments. (E) Cell cycle analysis on normal and HGPS fibroblasts at early and late passages, 
respectively. (F) Quantification of cell cycle analysis in E from two independent experiments. *P < 
0.05. 
 
To determine the effect of progerin on PARP1, normal SMCs were transfected 
with EGFP-progerin (EGFP-HG) or EGFP lamin A (EGFP-LA) and subsequently 
stained with an anti-PARP1 antibody. As shown in Figure 3-4A, the PAPR1 staining 
intensities were similar in the non-transfected cells (white arrows) as those in the cells 
expressing EGFP-LA or low amounts of EGFP-HG (green arrows). In contrast, in 
high expressers of EGFP-HG, PARP1 signals were significantly reduced (Figure 3-
4A). Quantification of fluorescence intensity further indicated that, as the amounts of 
EGFP-HG increased, PARP1 decreased at a significantly faster rate than when EGFP-
LA amounts increased (Figure 3-4B), supporting the belief that PARP1 reduction is 
associated with the amount of progerin.  
Next, to directly investigate the causative relationship between progerin 
accumulation and PARP1 down-regulation, increasing amounts of EGFP-HG were 
transfected and expressed in normal SMCs. I found that the levels of PARP1 
gradually decreased as the amounts of EGFP-HG increased (Figure 3-4C). 




PARP1 and EGFP-HG (R2 = 0.9818, Figure 3-4D). Notably, when progerin was 
ectopically expressed, a corresponding decrease of endogenous lamin A and C was 
observed (Figure 3-4C), implying a potential feedback loop in SMCs to control the 
total amount of A type lamins. Taken together, these results show that progerin 
resulted in PARP1 reduction in SMCs. In an attempt to address the functional 
importance of PARP1 in progerin-expressing cells, I applied a PARP1 inhibitor to the 
early passage HGPS fibroblasts, which expressed similar amounts of PARP1 as the 
control cells (Figure 3-3A). As shown in Figure 16E, HGPS fibroblasts showed much 
higher sensitivity to PARP1 inhibitor than normal control fibroblasts, suggesting an 










Figure 3-4: Progerin down-regulates PARP1. (A). Representative images of immunofluorescence 
staining with anti-PARP1 in normal SMCs transfected with pEGFP-C1-LA or pEGFP-C1-HG 
plasmids. The transfected and untransfected cells are indicated by green and white arrows, respectively. 
The nuclei were outlined by white dashed lines. (Scale bar, 20 μm.) (B). Quantification of A, showing 
the correlation between EGFP-HG or EGFP-LA fluorescence intensity (x axis) and PARP1 fluorescent 
intensity (y axis). More than 100 cells were randomly picked for each group. (C). Western blot with 
anti-PARP1 and GAPDH antibodies on normal SMCs transfected with different amounts of pEGFP-
C1-HG plasmid. (D). Quantification of F, showing a negative-linear relationship between PARP1 (y 
axis) and progerin (x axis) protein amounts. Signals were normalized to the untransfected control. (E). 
Survival curve of early passage normal and HGPS fibroblasts upon a PARP1 inhibitor (Olaparib) 
treatment. Results were generated from two independent experiments. *P < 0.05. 
 
3.2.3 PARP1 mis-localization is associated with disrupted Ran gradient in HGPS 
SMCs. 
To investigate how progerin down-regulated PARP1, I compared PARP1 
mRNA levels in normal and HGPS SMCs using RT-qPCR. Furthermore, I 
overexpressed progerin in normal SMCs and examined its effect on PARP1 
transcription (Figure 3-5A & B). These data revealed no major changes in mRNA 
levels of PARP1 in those progerin-expressing SMCs, suggesting the observed down-
regulation of PARP1 might result from compromised protein maintenance.  
To examine how progerin may affect PARP1 protein stability, I overexpressed 
PARP1-GFP as described previously (Haince et al., 2008), together with DsRed-LA 
or DsRed-HG in normal SMCs. As expected, PARP1-GFP was localized inside the 
nucleus when co-expressed with the vector control or DsRed-LA (Figure 3-6A). In 
addition, consistent with a previous study (Boamah et al., 2012), I observed that 
PARP1-GFP became concentrated in the nucleoli when over expressed (Figure 3-
6A), reflecting its roles in ribosome biogenesis. However, in DsRed-HG transfected 




GFP (Figure 3-6A & B). These results implied that accumulated progerin excluded a 
fraction of PARP1 from the nucleus, and this fraction might be subjected to 
protease/proteasome mediated degradation.  
 
 
Figure 3-5: PARP1 mRNA level was not significantly affected by progerin. (A). RT-qPCR with 
PARP1-specific primers on normal and HGPS SMCs at days 14, 21, and 28. No significant changes of 
PARP mRNA levels were detected. (B). RT-qPCR with PARP1-specific primers on normal SMC 
samples transfected with indicated amounts of pEGFP-C1-HG plasmids. No significant changes of 
PARP1 mRNA levels were detected. 
 
Next, I tested whether blocking farnesylation of progerin could restore PARP1’s 
normal localization. To study this possibility, I used HG-SSIM, a non-farnesylatable 
mutant of progerin that carries a cysteine to serine mutation on the CSIM motif at the 
C terminus (Capell et al., 2005), and co-expressed it with PARP1-GFP in normal 
SMCs. As reported previous (Capell et al., 2005), DsRed-HG-SSIM no longer located 




nucleoplasm (Figure 3-6A). Importantly, in the majority of the DsRed-HG-SSIM-
transfected cells, I observed that the normal nuclear localization of PARP1-GFP was 
restored (Figure 3-6A). Quantification revealed that the percentage of PARP1-
mislocalized cells was significantly decreased to 10% in the DsRed-HG-SSIM-
expressing cells, compared with roughly 30% in DsRed-HG-expressing cells (Figure 
3-6B). To further confirm this result, a FTI was used to treat DsRed-HG-expressing 
cells. As expected, the FTI treatment also rescued the mis-localization phenotype of 
PARP1-GFP and significantly reduced the mis-localized population (Figure 3-6A & 
B). These data suggested that the abnormal anchorage of progerin to the nuclear 
envelope was the main cause of the PARP1 mis-localization.  
 
Figure 3-6: Progerin induces PARP1 mis-localization. (A) Representative images showing normal 
SMCs coexpressing PARP1-GFP with DsRed, DsRed-LA, DsRed-HG (with or without 2 μM FTI), or 
DsRed-HG-SSIM. Nuclei were outlined by white dashed lines. (Scale bar, 10 μm.) (B) Quantification 
of A, showing the percentage of PARP1-GFP– mislocalized cells under indicated conditions. More 
than 100 cells were counted for each group. Results were generated from three independent 





I speculated that the PARP1 mis-localization in HGPS SMCs might be caused 
by a compromised nuclear import system mediated by a disrupted Ran gradient, 
which has been reported in HGPS fibroblasts (Kelley et al., 2011; Snow et al., 2013). 
To test this idea, I first examined the Ran gradient in normal and HGPS SMCs at days 
7, 14, and 21 using immunofluorescence. As shown in Figure. 3-7A, HGPS SMCs 
displayed significantly decreased Ran signals in the nucleus, compared with the 
control cells, indicating that the Ran gradient [nuclear/cytoplasmic (N/C) ratio, 
(Figure 3-7B)] was disrupted in HGPS SMCs. Moreover, HGPS SMCs at days 14 and 
21 exhibited even lower N/C ratios than the same cells at day 7 (Figure 3-7B), which 
is in agreement with the observation of a gradual reduction of PARP1 levels over 
time in HGPS SMCs. To further test the correlation between Ran gradient disruption 
and PARP1 mis-localization, HGPS SMCs at day 14 were transfected with PARP1-
GFP and subsequently stained with Ran antibody. About 30% of the transfected 
HGPS SMCs displayed the PARP1 mis-localization phenotype (Figure. 3-8A). 
Importantly, these cells also showed significantly lower N/C ratios compared with the 
cells with normal nuclear PARP1-GFP (Figure 3-8B). Similar to Figure 18A, I 
examined the Ran gradient in normal SMCs transfected with DsRed-HG or DsRed-
LA. Unlike LA, which did not interfere with the Ran gradient (Fig. 21A), HG 
expression significantly weakened nuclear signals of Ran (Figure 3-9A). 
Quantification revealed that the N/C ratios of Ran negatively correlated with progerin 
amounts (Figure 3-9B). Furthermore, inhibition of progerin farnesylation through FTI 
or HG-SSIM mutant rescued the Ran gradient disruption (Figure 3-9A & B). 




envelope disrupted Ran gradients, thereby affecting the nuclear import of PARP1 in 
HGPS SMCs. 
 
Figure 3-7: HGPS SMC display disrupted Ran gradient. (A) Representative images of 
immunofluorescent staining with an anti-Ran antibody on normal and HGPS SMCs at days 7, 14, and 
21. Ran gradient was denoted as Ran (N/C). N and C refer to the nucleus and cytoplasm, respectively. 






Figure 3-8: PARP1 mis-localization is associated with Ran gradient disruption in HGPS SMCs. (A). 
Representative images of immunofluorescence staining with anti- Ran antibody on HGPS SMCs 
transfected with PARP1- GFP. Cells with both normally or mislocalized PARP1- GFP were shown. 
The nuclei were outlined by white dashed lines. (Scale bar, 20 μm.) (B). Quantification of C, showing 






Figure 3-9: Progerin disrupts Ran gradient. (A). Representative images of immunofluorescence 
staining with anti- Ran antibody in normal SMCs transfected with DsRed, DsRed-LA, DsRed-HG 
(with or without 2 μM FTI) or DsRed-HG-SSIM. The transfected and untransfected cells were 
indicated by green and white arrows, respectively. The nuclei were outlined by white dashed lines. 
(Scale bar, 20 μm.) (B). Quantification of E, showing the correlation between DsRed fluorescent 
intensity and Ran gradient (Ran N/C) in N and C refer to the nucleus and cytoplasm, respectively. 




3.2.4 Compromised HR and activated NHEJ in S/G2 phase HGPS SMCs. 
Previous studies reported that inhibition or silencing of PARP1 could lead to 
cell death in HR-deficient cells, due to NHEJ activation and consequent chromosome 
mis-arrangements (Bunting et al., 2010). Given PARP1’s essential function in HR-
deficient cells, I next examined the repair efficiencies of HR and NHEJ in HGPS 
SMCs. 
Because HR is the major mechanism for replication-associated DSB repair in 
S/G2 phase, I induced DNA damage with CPT again to mimic replication fork 
collapse (Rothkamm et al., 2003). Different from the CPT experiment shown in 
Figure 3-1, here, CPT was used at a very low concentration (100 nM), thus only S/G2 
phase cells were affected and no global apoptosis was induced (Ray Chaudhuri et al., 
2012). At 10 min, 30 min, 120 min, and 720 min after CPT treatment, γH2AX and 
Rad51 signals were examined using immunofluorescence. After 10 min of CPT 
treatment, γH2AX foci were clearly identified in both normal an HPGS-SMCs, 
indicating that CPT had induced DSBs in both (Figure 3-10A). Rad51 plays an 
essential role in HR-mediated DSB repair. In normal SMCs, the formation of Rad51 
foci started to appear at the 30-min time point, and at 720 min, most of these foci 
became co-localized with γH2AX foci (Figure 3-10A). Conversely, no distinct Rad51 
foci were observed in HGPS SMCs throughout the whole time course (Figure 3-10A). 
To elucidate this phenomenon, over 100 cells were randomly picked at each time 
point, and each cell was plotted according to the numbers of γH2AX and co-localized 
Rad51 foci (as x and y). In normal SMCs, Rad51 foci became increasingly co-




during the time course. However, in HGPS SMCs, the slope of the trend line 
remained around 0 at all every point (Figure 3-10B), revealing a completely defective 
HR in these HGPS SMCs. Notably, the percentage of γH2AX-positive nuclei in 
Figure 3-10C is reduced in HGPS SMCs compared with normal controls under 
100nM CPT treatment, probably due to the reduced S phase cell population in HGPS 
SMCs (Figure 2-7C).  
With decreased PARP1 and a completely defective HR, DSBs will be fixed 
through the error-prone mechanism NHEJ. Indeed, in HGPS SMCs, the percentile of 
γH2AX-positive nuclei and the average number of γH2AX foci in each nucleus were 
gradually reduced after CPT treatment (Figure 3-10B & C), suggesting the NHEJ 
pathway was active in repairing these DSBs caused by CPT. 53BP1 can promote an 
NHEJ response to DNA damage (Bothmer et al., 2010). To assay the activity of 
NHEJ in S/G2 phase HGPS SMCs, I checked the formation of 53BP1 foci after 
100nM CPT treatment. I found that, whereas no apparent 53BP1 foci formed in 
normal SMCs, distinct 53BP1 foci started to co-localize with γH2AX at 10 min after 
treatment in HGPS SMCs (Figure 3-11A & B), suggesting that normal SMCs used 









Figure 3-10: HGPS SMCs show impaired HR and activated NHEJ. (A). Representative image 
showing immunofluorescence staining with anti-γH2AX and Rad51 antibodies on normal and HGPS 
SMCs recovered for various amounts of time after 100 nM CPT treatment. (Scale bar, 10 μm.) (B). 
Quantification of A, showing the number of γH2AX (x axis) and colocalized Rad51 (y axis) foci in 
normal and HGPS SMCs at different time points. More than 100 cells were counted for each case. The 
trend lines of normal (in gray) and HGPS (in red) SMCs were also presented. (C). The percentage of 
nuclei containing more than five γH2AX foci in normal and HGPS SMCs at each indicated time point 







Figure 3-11: NHEJ is over-activated in HGPS SMCs during S/G2 phase. (A). Representative images 
of immunofluorescence staining with anti-γH2AX and 53BP1 antibodies on normal and HGPS SMCs 
at 10 min after 100 nM CPT treatment. (Scale bar, 10 μm.) (B). Quantification of D, showing the 
number of γH2AX (x axis) and colocalized 53BP1 (y axis) foci in normal and HGPS SMCs at different 
time points. Over 50 cells were analyzed. 
 
3.2.5 Mitotic catastrophe in HGPS SMCs 
Based on the observations of increased caspase-independent cell death, down-
regulated PARP1, defective HR, and activated NHEJ, I hypothesized that DSBs were 
repaired incorrectly by NHEJ, which resulted in problems during mitotic division, 
leading to a mitotic catastrophe of HGPS SMCs. To test this hypothesis, cell cycle 
analysis was performed at days 14, 21, and 28 in SMC differentiation medium. 
Consistent with the data shown in Figure2-7, at each time point, I observed a 
significant increase in the G2/M population and a corresponding reduction in S phase 
population in HGPS SMCs compared with the normal control (Figure 3-12). This 
observation further supported the notion that mitosis is defective in HGPS. Taken 






Figure 3-12: HGPS SMCs arrest at G2/M phase. Cell cycle analysis of the normal and HGPS SMCs at 
denoted time points. Results were generated from two biological replicates. 
 
Next, to directly visualize the M phase of HGPS SMCs, I performed differential 
interference contrast (DIC) live cell imaging. Whereas all normal SMCs proceeded 
through mitosis smoothly (Figure 3-13A, top), HGPS SMCs either died and were 
destroyed during cell division (mitotic catastrophe) or exited mitosis without dividing 
but survived (Figure 3-13A, middle and bottom, respectively). Statistical analysis 
confirmed that about 50% of the HGPS SMCs displayed mitotic catastrophe, and the 
rest failed to divide (Figure 3-13B). In support of this observation, metaphase spectral 
karyotyping revealed ∼6.7% aneuploidy and 20% polyploidy in dividing HGPS 
SMCs (Figure 3-14A & B). Next, a BrdU pulse-chase experiment was conducted to 
follow the fate of S phase SMCs. 48 and 96 h after the BrdU pulse, 
immunofluorescence staining of BrdU was carried out. In normal SMCs, the 
percentage of the BrdU positive nuclei gradually increased from 20% to 80%, 
reflecting normal cell division. In contrast, the BrdU-positive nuclei in HGPS SMCs 




(Figure 3-15). This result indicated that over 60% of the S phase HGPS SMCs were 






Figure 3-13: Mitotic catastrophe in HGPS SMCs. (A). DIC live cell imaging of normal and HGPS 
SMCs at day 21. (Top) Normal mitotic division of a normal SMC; (Middle) mitotic catastrophe of an 
HGPS SMC; and (Bottom) failed mitosis of an HGPS SMC. (b). Percentage of normal and defective 






Figure 3-14: HGPS SMCs bear abnormal karyotype. (A). Representative spectral karyotypes of 
normal and HGPS SMCs at day 14. Red arrows refer to chromosome re-arrangements and aneuploidy 
in HGPS SMCs. (B). Quantification of A, showing the percentage of aneuploidy and polyploidy in 
normal and HGPS SMCs. The asterisk indicated 0% of aneuploidy or polyploidy in normal SMCs. A 









Figure 3-15: HGPS SMCs fails to proceed through cell division. Quantification of the percentages of 
BrdU-positive nuclei at 48 h and 96 h after BrdU pulse in normal and HGPS SMCs at day 14. Results 





3.3.1 PARP1 is a key regulator of SMC survival in Progeria 
Efforts to test the role of caspase 3 in HGPS SMC cellular death led to negative 
results, suggesting that this phenotype was carried out through caspase 3 independent 
mechanisms (Figure 3-1). However, during this process, I found that PARP1, an 
important protein involved in DNA damage repair and cellular homeostasis, was 




this important role of PARP1, I wondered whether its down-regulation contributed to 
the cell death phenotype in HGPS SMCs. 
In addition to its well-recognized role in DNA SSB repair, several studies 
revealed a new role of PARP1 in protecting HR and suppressing NHEJ (Hochegger et 
al., 2006; Patel et al., 2011). Here, I found that the PARP1 protein levels were 
reduced in HGPS SMCs after day 14 in SMC culture as well as in late passage HGPS 
fibroblasts (Figure 3-1C & G and Figure 3-2A & B). Importantly, the progerin 
overexpression (Figure 3-4A-D) revealed a direct inverse relationship between the 
amounts of PARP1 and progerin, indicating that progerin is a powerful suppressor of 
PARP1. The PARP1 inhibitor experiment in HGPS fibroblasts further revealed an 
essential role of PARP1 in cell survival (Figure 3-1E). I speculate that the sensitivity 
of PARP1 to progerin may vary in different cell types. In fibroblasts, PARP1 may be 
less influenced by progerin accumulation than in SMCs. Therefore PARP1 down-
regulation was not obvious until late passage fibroblast cells. These data also suggest 
that PARP1 is indispensable in all progerin-expressing cell types, and the levels of 
PARP1 reduction may be positively correlated with the severity of phenotypes in 
HGPS patients.  
My next question was how does progerin inhibit PARP? Quantitative RT-PCR 
analysis showed a slight, insignificant reduction in PARP1 mRNA in the presence of 
progerin, suggesting that progerin likely affects PARP1 post-translationally (Figure 3-
5). Microscopy analysis further revealed that a fraction of PARP1 was mis-localized 
to the cytosol in the presence of large amounts of progerin (Figure 3-2), and this 




of progerin to the nuclear envelope (Figure 3-2). Previous studies demonstrated 
abnormal nuclear pore clustering and a disrupted Ran gradient across the nuclear 
membrane in HGPS fibroblasts (Kelley et al., 2011; Snow et al., 2013). I speculated 
that this mis-localization of PARP1 was a novel effect of the disrupted RanGTP 
gradient. Indeed, a weakened Ran gradient (Figure 3-7) and a strong correlation 
between these two (Figure 3-9) were found in HGPS SMCs.  
It has been shown that NHEJ is active in all cell cycle phases, whereas HR is 
particularly important in S/G2. Moreover, DSBs produced by replication fork 
inhibitors are primarily repaired by HR. Using a topoisomerase I inhibitor (CPT) at a 
nanomolar concentration that only affects S/G2 phase cells, my analysis revealed a 
completely deficient HR and an elevated NHEJ response in S phase HGPS SMCs 
(Figure 3-10 and Figure 3-11). When the error-prone NHEJ pathway is used in DNA 
repair, irreversible chromosome aberrations can occur, resulting in complicated 
consequences (Bunting et al., 2010; Patel et al., 2011). Most commonly, cells will 
spend more time in M phase, attempting to resolve the problems (Vitale et al., 2011). 
If entangled chromosomes are unresolvable, cells will die through mitotic catastrophe 
(Vitale et al., 2011). Indeed, my cell cycle analysis revealed a palpable G2/M delay in 
HGPS SMCs (Figure 3-12) and late passage fibroblasts (Figure 3-3E & F), suggesting 
that these cells were encountering problems during cell division. Live cell imaging 
and spectral karyotyping experiments further demonstrated that HGPS SMCs either 
died in mitosis or failed to divide, forming bi-nucleated cells (Figure 3-13 and Figure 
3-14). An additional line of supportive evidence arose from a BrdU pulse-chase 




proceed through the M phase (Figure 3-15). Previous studies also have shown mitotic 
delay and bi-nucleation in HGPS fibroblast cells (Cao et al., 2007). Again, the mitotic 
delay and cell death in HGPS SMCs were more prominent than those observed in 
HGPS fibroblasts, possibly due to a greater PARP1 reduction in HGPS SMCs.  
DNA damage has long been implicated in HGPS pathogenesis. In 2005, the 
Zhou group published a study elucidating a deficient HR, an overactive NHEJ, and 
defective DNA damage repair in primary HGPS fibroblasts and mouse embryonic 
fibroblasts (MEFs) from a progeria model (Liu et al., 2005). In 2011, Zhang and 
colleagues generated the first iPS cell model for HGPS and reported increased DNA 
damage in differentiated HGPS SMCs (Zhang et al., 2011). In addition, Liu et al. 
reported a decrease of DNA PKCs in differentiated HGPS SMCs, an enzyme with an 
established role in the NHEJ response (Liu et al., 2011). In line with these previous 
reports, I reported a previously unidentified and essential role of PARP1 in mediating 
DNA damage repair and SMC survival in HGPS. My data can be summarized in a 
model: the accumulation of progerin causes PARP1 down-regulation, which results in 
the activation of the NHEJ pathway in the HR deficient HGPS SMCs. The error-
prone NHEJ further leads to chromosome aberrations and mitotic catastrophe in 
HGPS SMCs 
 
3.3.2 Insights into future therapeutics of HGPS and normal vascular aging. 
Based on my model, to rescue the SMC loss in HGPS, one solution is to restore 
normal HR function. Whereas the precise pathway for progerin to interfere with HR 




One emerging hypothesis is that progerin disrupts chromatin remodeling after DSBs, 
hence blocking the access of DNA damage repair factors to damaged regions. This 
idea is supported by a number of studies demonstrating global changes in genome 
organization and the epigenome in HGPS cells (McCord et al., 2013; Shumaker et al., 
2006). Importantly, recent studies have suggested that changes in H3K9me3 levels in 
HGPS cells can affect genome maintenance and the compromised ATM-mediated 
phosphorylation of KAP-1 impairs DNA repair in Zmpste24-deficient MEFs (Liu et 
al., 2013a; Liu et al., 2013b), providing a possible molecular connection between 
chromatin modifications and the DNA repair machinery. Other lines of studies have 
suggested a role of Xeroderma pigmentosum group A (XPA) protein in excluding 
normal access of DNA repair machinery to DSBs in HGPS cells (Musich and Zou, 
2009, 2011). Whereas the detailed mechanisms underlying HR deficiency in HGPS 
are still being elucidated, I predict that specific treatments that promote targeting of 
HR repair proteins to DSB termini are expected to reduce or diminish the SMC loss 
phenotype associated with progerin accumulation.  
Increasing evidence suggests the involvement of progerin in the normal aging 
process (Cao et al., 2011a; McClintock et al., 2007; Scaffidi and Misteli, 2006). 
Significantly, overlapping cardiovascular pathology was identified in HGPS and 
geriatric patients (Olive et al., 2010). Additional studies demonstrated an 
accumulation of unprocessed farnesylated prelamin A (a longer version of progerin) 
in the vasculature (Liu et al., 2013c; Ragnauth et al., 2010). It will be of great interest 
to determine whether HR becomes partially impaired in the aged vasculature and 




normal vascular aging. In summary, the present study uncovers what I believe is the 
first study to elucidate the DNA damage response pathway underlying the vascular 



































Chapter IV: Cell cycle dependent characterization of 
homologous recombination and non-homologous end joining 















Non-homologous end joining (NHEJ) and homologous recombination (HR) are 
the two major pathways used by eukaryotic cells to repair DSBs (Branzei and Foiani, 
2008). The choice between these two pathways is largely decided by the specific cell 
cycle phase (Branzei and Foiani, 2008). For example, NHEJ is the predominant DSB 
repair pathway during the G0/G1 phase, due to the nature of more condensed 
chromatin and the absence of sister chromatid as repairing template (Branzei and 
Foiani, 2008; Chapman et al., 2012). On the other hand, HR activity is mostly 
observed in S/G2 phase cells, where chromatin structure is less compact and sister 
chromatids are available (Branzei and Foiani, 2008; Chapman et al., 2012). During 
S/G2 phase, the Ku70-Ku80 heterodimer complex can still bind to DSB ends with 
extremely high affinity, which is in favor of NHEJ upon DSBs (Branzei and Foiani, 
2008). Interestingly, HR manages to compete with NHEJ during S/G2 phase with the 
help from additional factors including BRCA1, CtIP, PARP1 and CDKs (Branzei and 
Foiani, 2008).  
Proper activation of NHEJ or HR at the correct cell cycle phase is crucial for 
eukaryotic cells to defend against genotoxic stress. Disruption of these processes 
could result in chromatin relocation, genome instability and cell death. For example, 
mutants that are defective in either NHEJ or HR express higher sensitivity to ionized 
radiation (IR) during G0/G1 phase or S/G2 phase respectively (Branzei and Foiani, 
2008). In chicken DT40 cells, a Ku70 knockout mutant (NHEJ defective) is 
extremely sensitive to IR during G0/G1 phase, suggesting a protecting role of NHEJ 




Rad54 knockout mutant (HR defective) exhibit higher IR sensitivity exclusively 
during S/G2 phase (Branzei and Foiani, 2008; Takata et al., 1998). Similarly, NHEJ 
defective mouse cells also showed elevated IR sensitivity during G0/G1 phase but not 
in S/G2 phase cells (Branzei and Foiani, 2008; Singh et al., 2009). In yeast, haploid 
cells during G0/G1 phase reply on NHEJ to repair DSBs, whereas diploid cells 
upregulate HR and suppress NHEJ (Astrom et al., 1999; Branzei and Foiani, 2008; 
Lee et al., 1999). These reports illustrated a cell cycle dependent activation of NHEJ 
or HR upon DSBs.  
Besides repair deficiencies, inappropriate activation of NHEJ may also lead to 
problems. In contrast to HR, which is directed by homology based DNA repair, NHEJ 
simply re-ligates two random DNA break ends at proximity (Lieber, 2010). 
Therefore, it is error prone and likely to introduce DNA mutations, insertions or 
deletions (Lieber, 2010). It has been previous shown that PARP1 deletion or 
inhibition leads to massive cell death in HR deficient cells, due to increased DSBs 
and over-activation of NHEJ (Bunting et al., 2010; Patel et al., 2011). Moreover, 
abrogation of NHEJ by 53BP1 knockout has been shown to restore HR and promote 
cell survival upon PAPR1 inhibition, suggesting a toxic role of NHEJ in genome 
instability (Bunting et al., 2010).  
In the previous chapter, I characterized HR and NHEJ efficiencies in S/G2 
phase HGPS SMCs. In this chapter, I aim to establish a complete cell dependent 
activation profile of HR and NHEJ in HGPS cells. Here, I present data showing that 




fibroblasts. HR is defective in both G0/G1 and S/G2 phase HGPS fibroblasts, 





4.2.1 Homologous recombination is deficient during G0/G1 and S/G2 phase 
HGPS fibroblasts. 
To assay HGPS HR activity at different cell cycle stages, I incubated normal 
and HGPS fibroblasts with BrdU for 30min. G0/G1 phase and S/G2 phase cells were 
indicated by BrdU negative and positive staining respectively. After BrdU labeling, 
cells were then treated with 1M doxorubicin (Dox), a topoisomerase II inhibitor, for 
DSB induction. To specifically examine HR efficiency, I tested the recruitment 
dynamics of BRCA1 and Rad51 (two important HR factors) at 30min, 120min and 
360min after Dox treatment. As shown in Figure 4-1 A, normal cells displayed a 
gradual increase of BRCA1 foci count during G0/G1 phase (BrdU negative), while 
HGPS fibroblasts failed to show any BRCA1 formation. Quantification of foci 
number showed a significant reduction of BRCA1 foci formation in HGPS fibroblasts 
(Figure 4-1B). Similar activation pattern was also observed on Rad51 recruitment 
(Figure 4-2). These data indicate that HR is inactive in G0/G1 phase HGPS 








Figure 4-1: HR is deficient in G0/G1 phase HGPS fibroblasts. (A). Representative image showing 
immunofluorescence staining with anti-BrdU and BRCA1 antibodies on normal and HGPS fibroblasts 
recovered for various amounts of time after 1M Dox treatment. (Scale bar, 5 μm.). (B). Quantification 







Figure 4-2: HR is deficient in G0/G1 phase HGPS fibroblasts. (A). Representative image showing 
immunofluorescence staining with anti-BrdU and Rad51 antibodies on normal and HGPS fibroblasts 
recovered for various amounts of time after 1M Dox treatment. (Scale bar, 5 μm.). (B). Quantification 







Figure 4-3: HR is deficient in S/G2 phase HGPS fibroblasts. (A). Representative image showing 
immunofluorescence staining with anti-BrdU and BRCA1 antibodies on normal and HGPS fibroblasts 
recovered for various amounts of time after 1M Dox treatment. (Scale bar, 5 μm.). (B). Quantification 






Figure 4-4: HR is deficient in S/G2 phase HGPS fibroblasts. (A). Representative image showing 
immunofluorescence staining with anti-BrdU and Rad51 antibodies on normal and HGPS fibroblasts 
recovered for various amounts of time after 1M Dox treatment. (Scale bar, 5 μm.). (B). Quantification 





I next examined HR activities in S/G2 phase cells. As shown in Figure 4-3, 
normal fibroblasts at S/G2 phase (BrdU positive staining) started to show a robust 
BRCA1 foci formation as early as early 2h after Dox treatment, whereas such event 
did not start in corresponding HGPS fibroblasts until four hours later, suggesting a 
delayed HR in HGPS during S/G2 phase. Similar activation pattern was also observed 
on Rad51 recruitment (Figure 4-4). Notably, both normal and HGPS cells exhibit 
significantly stronger BRCA1 and Rad51 recruitments during S/G2 phase in 
comparison to G0/G1 phase, supporting a predominant role of HR during S/G2 phase 
(Figure 4-1 – 4-4) (Branzei and Foiani, 2008). 
To elucidate the molecular mechanism underlying HGPS HR deficiency, I 
performed western blotting analysis to measure the protein level of BRCA1 and 
Rad51 in HGPS fibroblast. Interestingly, both BRCA1 and Rad51 displayed a 
significant reduction in HGPS fibroblasts (Figure 4-5A). Moreover, RT-qPCR 
revealed that the mRNA level of these two HR factors were also significantly reduced 
in HGPS fibroblasts, suggesting that progerin might impact the expression of BRCA1 
and Rad51. Protein level reduction of HR factors could at least partially explain HR 





Figure 4-5: BRCA1 and Rad51 are down-regulated in HGPS fibroblasts. (A). Western blotting 
analysis with an anti-BRCA1 or Rad51 antibody on passage matched normal and HGPS fibroblasts. 
(B). RT-qPCR with BRCA1 and Rad51 specific primers on passage matched normal and HGPS 
fibroblasts.  
 
4.2.2 Non-homologous end joining is deficient in G0/G1 phase but functional in 
S/G2 phase HGPS fibroblasts. 
To characterize HGPS NHEJ efficiencies at different cell cycle phases, I 
examined the recruitment dynamics of RIF1, an NHEJ specific promoting protein, at 
10min, 30min 2h and 6h after Dox treatment. As shown in Figure 4-6A & B, G0/G1 
phase (BrdU negative staining) normal fibroblasts displayed robust recruitment of 
RIF1 as early as 10min after Dox treatment. This recruitment then further increased 
over time and peaked at 2h after Dox treatment. On the other hand, a comparable 
recruitment of RIF1 did not start in G0/G1 phase HGPS fibroblasts until two hours 
later (Figure 4-6), indicating a significant delay of NHEJ in HGPS fibroblasts during 




In Chapter III, I revealed an over-activation of NHEJ in HGPS SMCs during 
S/G2 phase, which resulted in chromosome relocation and cell death (Figure 3-13 – 
3-14). To further explore this phenotype, I examined the recruitment dynamics of 
RIF1 during S/G2 phase after Dox treatment. As shown in Figure 4-7, HGPS 
fibroblasts displayed a gradual formation of RIF1 foci in S/G2 phase after Dox 
treatment. These RIF1 recruitments were comparable to those in normal fibroblasts at 







Figure 4-6: NHEJ is impaired in G0/G1 phase HGPS fibroblasts. (A). Representative image showing 
immunofluorescence staining with anti-BrdU and RIF1 antibodies on normal and HGPS fibroblasts 
recovered for various amounts of time after 1M Dox treatment. (Scale bar, 5 μm.). (B). Quantification 










Figure 4-7: NHEJ is active in S/G2 phase HGPS fibroblasts. (A). Representative image showing 
immunofluorescence staining with anti-BrdU and RIF1 antibodies on normal and HGPS fibroblasts 
recovered for various amounts of time after 1M Dox treatment. (Scale bar, 5 μm.). (B). Quantification 









4.3.1 Mis-regulated NHEJ and HR throughout the cell cycle in HGPS. 
A proper cell cycle dependent activation of NHEJ and HR is a critical to 
maintain genome integrity and cellular homeostasis (Branzei and Foiani, 2008; 
Chapman et al., 2012; Escribano-Diaz et al., 2013; Takata et al., 1998). Deficiencies 
in NHEJ or HR increase cellular IR sensitivity during G0/G1 or S/G2 phase 
respectively (Branzei and Foiani, 2008). Significantly, mis-regulation of the NHEJ 
and HR pathway has been proposed to contribute to the premature aging and other 
defective phenotypes in HGPS animal models (Krishnan et al., 2011; Liu et al., 2005; 
Liu et al., 2013a; Liu et al., 2013b). In agreement with these reports, in the previous 
chapter, I demonstrated that deficient HR and over-activated NHEJ is responsible for 
the cell death phenotype in iPSC driven HGPS SMCs (Zhang et al., 2014). To portrait 
a comprehensive cell cycle dependent activation pattern of NHEJ and HR in HGPS, I 
introduced DSBs in BrdU labeled HGPS fibroblasts and measured NHEJ and HR 
using RIF1 and BRCA1/Rad51 as indicators respectively. My results demonstrated 
that HR is completely inactive in G0/G1 phase and significantly impaired in S/G2 
phase HGPS fibroblasts. As for NHEJ, I found it to be drastically impaired in G0/G1 
phase, but completely unaffected in S/G2 phase HGPS fibroblasts. These changes are 








Figure 4-8: Scheme of the cell cycle dependent activation of NHEJ and HR in normal and HGPS cells. 
In normal cells, NHEJ is predominantly activated in G0/G1 phase with a slight activity in S/G2 phase 
while HR is mostly active in S/G2 phase. In HGPS, NHEJ is significantly impaired in G0/G1 phase 
and active in S/G2 phase. HGPS HR is also significantly impaired in S/G2 phase and completely 
undetectable in G0/G1 phase. The efficiencies of NHEJ in S/G2 phase HGPS cells are cell type 
dependent. HGPS SMCs display over activated NHEJ during S/G2 phase while S/G2 phase HGPS 
fibroblasts display comparable NHEJ efficiency to that in normal. 
 
4.3.2 Mis-regulated NHEJ and HR induce various cellular defects in HGPS. 
HR deficiency during S/G2 phase is particularly toxic to cellular homeostasis, 
as it allows the error prone NHEJ to fix DSBs and increases the frequency of 
chromosome breaks and relocation (Bunting et al., 2010; Cao et al., 2009; Patel et al., 
2011). Consequently, aberrant chromosome structure may trigger a mechanism 
termed mitotic catastrophe and result in mitotic cell death (Castedo et al., 2004; Imreh 
et al., 2011; Vakifahmetoglu et al., 2008). This mechanism provides a plausible 
explanation for the cell death phenotype in HGPS SMCs (Zhang et al., 2014). 
Interestingly, the activity of NHEJ in S/G2 phase HGPS fibroblasts seems to be 
weaker than that in HGPS SMCs, since HGPS SMCs displayed significantly stronger 
NHEJ activity than corresponding normal SMCs whereas HGPS fibroblasts only 




activation during S/G2 phase might explain the differential severity of cell death 
between HGPS SMCs and HGPS fibroblasts. Defective NHEJ during G0/G1 phase is 
also problematic, as unfixed DSBs triggers sustained DNA damage response (DDR), 
which results in either apoptosis or cellular senescence (Chen et al., 2007; Jackson, 
2002; Robles and Adami, 1998).  
The molecular mechanism underlying HGPS NHEJ and HR disruption remains 
unclear. My preliminary study revealed that both BRCA1 and Rad51 were 
significantly down-regulated in HGPS fibroblasts, pointing out a potential mechanism 
that could contribute to HGPS HR deficiency. However, whether this down-
regulation is the only cause and how progerin induces such down-regulation remains 
to be uncovered. As for NHEJ, previous reports proposed that abnormal histone 
modifications and compact chromatin conformation serves as a barrier preventing the 
NHEJ regulator 53BP1 from loading to the damaged DNA lesion (Krishnan et al., 
2011; Liu et al., 2012; Liu et al., 2005; Liu et al., 2013a; Liu et al., 2013b). Direct 























Chapter V: Reduced ATM and H2AX DDR signals delay 















Defective DNA damage response (DDR) has been closely associated with 
genome instability and premature aging (Lombard et al., 2005). Abnormal DDR has 
been observed in HGPS fibroblast in vitro cultures and animal models (Krishnan et al., 
2011; Liu et al., 2005; Zhang et al., 2014). Specifically, in response to ionized 
irradiation, the recruitments of 53BP1 and Rad51, were significantly delayed in those 
cells, supporting compromised NHEJ and HR DSB repair pathways (Krishnan et al., 
2011; Liu et al., 2005; Zhang et al., 2014). I also observed a drastic delay in Rad51 
recruitment to DSBs in HGPS iPSC-differentiated smooth muscle cells, suggesting 
that the defective HR is a universal phenotype associated with multiple HGPS 
lineages (see Chapter III). Moreover, ectopic expression of progerin in HeLa cells 
also significantly impaired 53BP1 recruitment to DSBs and a direct inhibitory role of 
progerin in DNA damage repair was suggested (Manju et al., 2006).  
In the previous chapter, I characterized the efficiencies of NHEJ and HR at 
different cell cycle phases, using RIF1 and BRCA1/Rad51 as indicators respectively. 
Specifically, I revealed that NHEJ was impaired in G0/G1 phase, but still functional 
in S/G2 phase HGPS fibroblast. This finding is in accordance with previous reports 
that 53BP1 recruitment was delayed in unsynchronized HGPS fibroblasts upon 
ionized irradiation (Krishnan et al., 2011; Liu et al., 2005). Although tremendous 
efforts have been spent to understand this phenotype, the underlying molecular 
mechanism remains largely unknown.  
In this chapter, I aim to elucidate a molecular mechanism to explain the NHEJ 




variant H2AX at Serine 139 (H2AX) is a crucial histone modification that occurs 
very rapidly at DSBs (Kinner et al., 2008; Mah et al., 2010). As an upstream DDR 
signal, H2AX plays an essential role in initiating NHEJ DSB repair pathways (Mah 
et al., 2010). In a previous study, embryonic stem cells from H2AX deficient 
(H2AX/) mice displayed a delayed recruitment of DNA damage repair players, 
elevated sensitivity to ionizing irradiation and compromised genome integrity 
(Bassing et al., 2002). Mechanistically, H2AX phosphorylation was believed to 
recruit several down-stream DNA damage repair proteins including NBS1, MDC1, 
53BP1 and BRCA1 to the DSB site to fix DSBs (Bassing et al., 2002; Chapman and 
Jackson, 2008; Paull et al., 2000). Three kinases, ATM, ATR or DNAPK have been 
shown to carry out the phosphorylation of H2AX at DSBs (Burma et al., 2001; 
Kinner et al., 2008; Stiff et al., 2004; Ward and Chen, 2001). In addition, ATM kinase 
can mediate phosphorylation of adjacent H2AX, thereby amplifying H2AX signals 
and creating a positive feedback loop (Falck et al., 2005; Kinner et al., 2008; You et 
al., 2005). H2AX was also reported to facilitate DSB end joining by anchoring DNA 
break ends in close proximities and reducing chromosome density (Banath et al., 
2004; Bassing and Alt, 2004; Bouquet et al., 2006; Kinner et al., 2008; Mah et al., 
2010; Xie et al., 2004). Given such importance of H2AX phosphorylation in DNA 
damage repair, I identify H2AX signaling as a target to study NHEJ deficiency in 
HGPS. 
Here I report a reduction in H2AX signal strength in HGPS fibroblasts upon 
treatment with Doxorubicin (Dox), a DSB inducing agent. Interestingly, this 




cells, consistent with their NHEJ deficiency pattern. A similar reduction in H2AX 
response is also observed in G0/G1 phase HGPS cells upon treatment with 
Camptothecin (CPT), a different DSB inducing agent. The reduced amplification of 
H2AX signals consequently leads to a delay in NHEJ player recruitment and DSB 
repair. Furthermore, ATM activation is found to be impaired in HGPS fibroblasts 
upon DSBs. Finally, I show evidence supporting that the observed ATM inactivation 
in HGPS is closely correlated with the loss of H3K9me3 in HGPS fibroblasts. 
Restoration of H3K9me3 through treatment with methylene blue (MB), an anti-
oxidant known to rescue HGPS heterochromatin loss, can restore ATM activation, 
H2AX signal strength, and NHEJ in HGPS fibroblasts. My data identified H2AX 
signal mis-regulation as an underlying molecular mechanism to explain NHEJ 
deficiency in HGPS and also suggested a novel connection between the two 
prominent phenotypes (H3K9me3 loss and NHEJ deficiency) and provides 














5.2.1 HGPS fibroblasts show reduced H2AX responses upon Dox treatment. 
To study H2AX signals in HGPS, I first examined the basal number of H2AX 
foci in primary HGPS and normal control fibroblasts by immunofluorescence staining. 
As shown in Figure 5-1A & B, HGPS fibroblasts showed a slight but significant 
increase in the number of H2AX foci than the normal control (normal: 2.5±0.3 vs. 
HGPS: 4.6±0.7 foci/cell), which is consistent with previous reports that HGPS cells 
accumulated more DSBs (Liu et al., 2006; Liu et al., 2008; Musich and Zou, 2011). 
To further study H2AX responses upon DSBs, I induced DSBs in HGPS and normal 
control fibroblasts by treating cells with Dox, a DNA damage-inducing agent that 
causes DSBs by inhibiting topoisomerase II (Kurz et al., 2004). Immunofluorescence 
staining and confocal microscopy analysis revealed that Dox treatment induced rapid 
and robust H2AX responses in normal fibroblasts (Figure 5-2A). Notably, HGPS 
fibroblasts displayed significantly weaker H2AX signals compared with normal cells 
(Figure 5-2A). Quantitative fluorescence analysis measuring the total fluorescence 
intensity of H2AX further supported this reduction in HGPS (Figure 5-2B). Western 
blotting analysis showed that H2AX responses were reduced in HGPS cells (Figure 
5-2C & D), while total H2AX was unchanged (Figure 5-3), suggesting that the 
phenotype was due to a functional deficiency in phosphorylation instead of overall 








Figure 5-1: HGPS fibroblasts bear a slightly elevated basal level of H2AX. Representative 
fluorescence images of basal H2AX foci in normal and HGPS fibroblasts.  Scale Bar: 5m. 
Quantification of (A) showing the number of H2AX foci in each nucleus in normal and HGPS 
fibroblasts at the basal level. More than 100 cells were randomly picked for quantification. Results 






Figure 5-2: HGPS fibroblasts bear reduced H2AX response upon Dox treatment. (A). Representative 
fluorescence images of H2AX foci in normal and HGPS fibroblasts after Dox treatment. Scale Bar: 
5m. (B). Quantification of (A), showing relative H2AX green fluorescence intensities in normal and 
HGPS fibroblasts after Dox treatment. More than 100 cells were randomly picked for quantification. 
Results were presented as mean ± SEM. ***P < 0.001. (C). Western blotting analysis with anti-H2AX 
and anti-GAPDH antibodies on normal and HGPS fibroblasts after Dox treatment. (D). Quantification 
of (C), showing the relative H2AX band intensity in normal and HGPS fibroblasts after Dox 
treatment (normalized to GAPDH). Three independent experiments were performed. Results were 
presented as mean ± SEM. **P < 0.01. 
 
 
Figure 5-3: Total H2AX level is comparable between normal and HGPS fibroblasts. 
 
I speculated that the reduction in H2AX signals could potentially interfere with 
down-stream DNA damage repair in HGPS. To test this, HGPS and control 
fibroblasts were treated with 1M Dox for an hour and allowed to recover for 10min, 
30min, 2h, 6h, and 24h respectively. I then quantified the number of H2AX foci per 
nuclei at each time point. As shown in Figure 5-4 A & B, in normal cells, the 
numbers of H2AX foci decreased gradually over time, indicating successful repair of 
the DSBs induced by Dox treatment. In contrast, while HGPS cells displayed weaker 
H2AX signals at the beginning (10 min), these signals stayed largely unfixed even 




describing defective DNA damage repair in HGPS (Krishnan et al., 2011; Liu et al., 
2005; Liu et al., 2013a; Manju et al., 2006). 
 
 
Figure 5-4: Reduced H2AX response delays DNA damage repair in HGPS fibroblasts. (A). 
Representative fluorescence images of H2AX foci in normal and HGPS fibroblasts that were allowed 
to recover for indicated amounts of time after Dox treatment. Scale Bar: 5m. (B). Quantification of 
(E), showing the number of H2AX foci in each nucleus at each time point. More than 100 cells were 
randomly picked for quantification. Results were presented as mean ± SEM. ***P < 0.001. 
 
5.2.2 H2AX reduction is predominantly observed in G0/G1 phase HGPS 
fibroblasts. 
In Chapter IV, I revealed that NHEJ was delayed in G0/G1 but not in S/G2 
phase HGPS fibroblasts. I next wondered whether the HGPS H2AX signal reduction 
followed this pattern. To investigate the H2AX signal reduction phenotype in HGPS 
during the cell cycle, I labeled S/G2 phase cells with BrdU for 30min and then 




staining. I found that the BrdU-negative, G0/G1 phase HGPS fibroblasts displayed a 
significant reduction in H2AX staining (Figure 5-5A & B left panel). To my surprise, 
the BrdU-positive, S/G2 phase HGPS fibroblasts showed a similar level of H2AX 
signals as normal control cells (Figure 5-5A & B right panel). To further verify the 
phenotype in G0/G1 phase, I synchronized normal and HGPS fibroblasts to the 
G0/G1 phase using serum starvation. Western blotting study revealed that H2AX 
was significantly weaker in these G0/G1 synchronized HGPS fibroblasts, compared 
to that in the normal control cells (Figure 5-5C). Taken together, these data suggest 
that the reduction in H2AX responses mainly takes place during G0/G1 phase but 
not S/G2 phase in HGPS cells. This is in agreement with the NHEJ mis-regulation 





Figure 5-5: Reduction of H2AX response is cell cycle dependent in HGPS fibroblasts. (A). 
Representative fluorescence images of H2AX foci and BrdU staining in normal and HGPS fibroblasts 
after Dox treatment. G0/G1 and S phase were indicated by BrdU negative and positive staining 
respectively. Scale Bar: 5m. (B). Quantification of (A), showing relative H2AX green fluorescence 
intensity. More than 40 cells were counted for each group. Results were presented as mean ± SEM. 
(CN). Western blotting analysis with anti-H2AX and anti-GAPDH antibodies on serum starvation 
synchronized normal and HGPS fibroblasts after Dox treatment. 
 
5.2.3 The amplification of H2AX signal is reduced in G0/G1 phase HGPS 
fibroblasts. 
The reduction in H2AX signaling could be caused by either fewer number of 
H2AX foci or reduced intensities of individual foci. To distinguish between these 
two possibilities, I synchronized normal and HGPS fibroblasts to G0/G1 phase and 
quantified the number and the fluorescence intensity of H2AX foci after Dox 
treatment. My analysis showed that HGPS and normal control fibroblasts had 
comparable H2AX foci counts (normal: 40±1.6 vs. HGPS: 38±1.2), suggesting that 
similar numbers of DSBs were induced by Dox treatment in HGPS and normal cells. 
The result further implicated that the initial phosphorylation of H2AX at DSBs was 
unaffected in HGPS. On the other hand, the H2AX signal amplification was 
disturbed in HGPS as reflected by reduced size and fluorescence intensity of 
individual foci (Figure 5-6A). Line-profile analysis and quantification of the average 
H2AX foci intensity confirmed this observation (Figure 5-6B & C). To rule out the 
possibility that this phenotype was only specific to Dox-induced DSBs, I treated 
synchronized G0/G1 phase HGPS and normal control fibroblasts with Camptothecin 




topoisomerase I. Upon CPT treatment, HGPS and normal cells showed comparable 
H2AX foci counts (normal: 18±0.6 vs. HGPS: 21±0.9). Consistent with Dox, CPT 
treatment induced significantly weaker H2AX foci in HGPS G0/G1 phase 
fibroblasts (Figure 5-6D-F). These reductions upon either Dox or CPT treatment were 
further validated by western blotting analysis (Figure 5-6G). Together, these 
experiments suggested that it was not the initiation, but the amplification of H2AX 






Figure 5-6: The amplification of H2AX signal is reduced in G0/G1 phase HGPS cells after Dox and 
CPT treatment. (A). Representative fluorescence images of H2AX foci in serum starvation 
synchronized normal and HGPS fibroblasts after Dox treatment. Arrow points to the single H2AX 
foci in the enlarged square.  Scale Bar: 5m. (B). Line profile analysis of (A), showing the reduced 
H2AX foci fluorescence strength in HGPS fibroblasts after Dox treatment. Green fluorescence 
intensity (y axis) was plotted against distance (x axis) along the yellow line in (A). (C). H2AX foci 
intensity analysis of (A). Each dot represents the average fluorescence intensity of individual H2AX 
foci in a single nucleus. More than 100 cells were randomly picked for quantification. Results were 
presented as mean ± SEM. ***P < 0.001. (D). Representative fluorescence images of H2AX foci in 
serum starvation synchronized normal and HGPS fibroblasts after CPT treatment. Arrow points to the 
single H2AX foci in the enlarged square.  Scale Bar: 5m. (E). Line profile analysis of (D), showing 
the reduced H2AX foci fluorescence strength in HGPS fibroblasts after CPT treatment. Green 
fluorescence intensity (y axis) was plotted against distance (x axis) along the yellow line in (D). (F). 
H2AX foci intensity analysis of (D). Each dot represents the average fluorescence intensity of 
individual H2AX foci in a single nucleus. More than 100 cells were randomly picked for 
quantification. Results were presented as mean ± SEM. ***P < 0.001. (G). Western blotting analysis 
with anti-H2AX and anti-GAPDH antibodies on serum starvation synchronized normal and HGPS 
fibroblasts after Dox or CPT treatment. 
 
5.2.4 Weakened H2AX leads to a delayed recruitment of non-homologous end 
joining factors in G0/G1 HGPS cells. 
Non-homologous end joining (NHEJ) is the predominant DSB repair pathway 
in G0/G1 phase (Bassing et al., 2002; Chapman et al., 2012; Felgentreff et al., 2014; 
Mao et al., 2008; Zhang et al., 2014). To investigate the effect of the impaired 
H2AX signal amplification on NHEJ pathway, I examined the recruitment of RIF1, 
an NHEJ specific promoting protein. Co-localization analysis indicated that in normal 
cells, RIF1 was efficiently loaded onto DSBs and co-localized with strong H2AX 
foci (Figure 5-7A). Line-profile analysis confirmed this co-localization (Figure 5-7B). 




despite the presence of weak H2AX foci (Figure 5-7A & B). Notably, RIF1 protein 
level was unchanged in HGPS fibroblasts (Figure 5-8). Therefore, this delay was a 









Figure 5-7: Weakened H2AX leads to a delayed recruitment of non-homologous end joining (NHEJ) 
factors in G0/G1 HGPS cells. (A). Representative fluorescence images of H2AX foci and RIF1 foci in 
serum starvation synchronized normal and HGPS fibroblasts after Dox treatment. Arrow points to the 
single H2AX or RIF1 foci in the enlarged square.  Scale Bar: 5m. (B). Line profile analysis of (A), 
showing the reduced recruitment of RIF1 to H2AX foci in HGPS fibroblasts. Green (H2AX) and red 
(RIF1) fluorescence intensities (y axis) were plotted against distance (x axis) along the yellow line in 
(A). Stars indicated strong co-localization of RIF1 and H2AX. (C). Representative fluorescence 
images of H2AX foci and 53BP1 foci in serum starvation synchronized normal and HGPS fibroblasts 
after Doxorubicin treatment. Arrow points to the single H2AX or 53BP1 foci in the enlarged square.  
Scale Bar: 5m. (D). Line profile analysis of (C), showing the reduced recruitment of 53BP1 to 
H2AX foci in HGPS fibroblasts. Green (H2AX) and red (53BP1) fluorescence intensities (y axis) 
were plotted against distance (x axis) along the yellow line in (C). Stars indicated strong co-
localization of 53BP1 and H2AX. (E). Quantification of (A), showing the number of H2AX (x axis) 
foci and co-localized RIF1 (y axis) foci per nuclei in normal and HGPS fibroblasts after Dox treatment. 
More than 100 cells were randomly picked for quantification. (F). Quantification of (C), showing the 
number of H2AX (x axis) foci and co-localized 53BP1 (y axis) foci per nuclei in normal and HGPS 
fibroblasts after Dox treatment. More than 100 cells were randomly picked for quantification. 
 
 
Figure 5-8: RIF1 protein level was comparable between normal and HGPS fibroblasts. 
 
Similar to RIF1, 53BP1, an important NHEJ player upstream of RIF1 (Chapman 
et al., 2013; Escribano-Diaz et al., 2013; Zimmermann et al., 2013), was also found to 
be inefficiently recruited to H2AX foci in HGPS G0/G1 phase cells (Figure 5-7C & 
D). This observation was in agreement with a previous report that 53BP1 recruitment 




Quantification indicated that at the same level of DNA damage, normal cells were 
able to recruit more RIF1 and 53BP1 to DSB sites than HGPS fibroblasts (Figure 5-
7E & F). Collectively, these data suggest that compromised amplification of H2AX 
signals upon DSBs affects the recruitment of NHEJ factors and delay DNA damage 
repair in G0/G1 phase HGPS fibroblasts. 
 
5.2.5 H2AX reduction is associated with defective ATM activation in HGPS. 
Three types of kinases (ATM, ATR and DNAPK) have been previously 
reported to phosphorylate H2AX upon DSBs (Burma et al., 2001; Kinner et al., 2008; 
Stiff et al., 2004; Ward and Chen, 2001). To determine which kinase mediates the 
phosphorylation of H2AX upon Dox treatment in G0/G1 cells, western blotting 
analysis was performed to examine the activation of these three kinases in G0/G1 
synchronized normal and HGPS fibroblasts. Upon Dox treatment, ATM was activated 
in normal cells as shown by an increased amount of phosphorylated ATM (pATM, 
S1981) (Figure 5-9A & B) (Bakkenist and Kastan, 2003). In contrast, pATM was 
significantly weaker in HGPS fibroblasts after Dox treatment (Figure 5-9A & B). 
Dosage-dependent Dox treatment further confirmed this difference between normal 
and HGPS fibroblasts (Figure 5-9C). These results were in agreement with a previous 
report that Zmpste24 deficient mouse embryonic fibroblasts (a progeroid like MEF 
that mimics HGPS) exhibited lower ATM activation upon ionized irradiation (Liu et 
al., 2013a). Interestingly, the level of total ATM seemed to be reduced in HGPS cells 
(Figure 5-9A & C). This down-regulation of protein amount could potentially 




was still significantly lower in HGPS cells, implying additional mechanisms to 
impede ATM activation upon Dox treatment (Figure 5-9B). In contrast to ATM 
activation, I didn’t detect observable activation of the other two kinases: ATR and 
DNAPK, upon Dox treatment (Figure 5-9D & E) (Chan et al., 2002; Zhao and 






Figure 5-9: H2AX signal reduction was caused by defective ATM activation in HGPS. (A). Western 
blotting analysis with anti-pATM(S1981), anti-ATM and anti-GAPDH antibodies on serum starvation 
synchronized normal and HGPS fibroblasts with or without Dox treatment. ATM activation was 
indicated by phosphorylated ATM(S1981). (B). Quantification of relative pATM(S1981) band 
intensity (normalized to total ATM) in normal and HGPS fibroblasts after Dox treatment. Five 
independent experiments were performed. Results were presented as mean ± SEM. ***P < 0.001. (C). 
Western blotting analysis with anti-pATM(S1981), anti-ATM, anti-H2AX and anti-GAPDH 
antibodies in normal and HGPS fibroblasts treated with indicated concentrations of Dox. (D). Western 
blotting analysis with anti-pCHK1(S345), anti-CHK1 and anti-GAPDH antibodies on normal and 
HGPS fibroblasts after Dox treatment. ATR activation was indicated by phosphorylation of 
CHK1(S345). (E). Western blotting analysis with anti-pDNAPK(T2609), anti-DNAPK and anti-
GAPDH antibodies on normal and HGPS fibroblasts after Dox treatment. DNAPK activation was 
indicated by phosphorylation of DNAPK(T2609). 
 
Next, to directly assay whether the amplification of H2AX phosphorylation was 
dependent on ATM activation, I examined H2AX responses in the presence of an 
ATM-specific inhibitor (KU-55933). As expected, incubation with the ATM inhibitor 
prior to Dox treatment led to a significant reduction in H2AX signals in both normal 
and HGPS fibroblasts (Figure 5-10A). Quantification showed a gradual reduction of 
both pATM and H2AX with increasing amounts of the ATM inhibitor (Figure 5-
10B). Since H2AX signals were crucial for 53BP1 recruitment at DSBs, I wondered 
whether ATM inhibitor could directly impair 53BP1 recruitment. Notably, normal 
fibroblasts treated with ATM inhibitor showed a significantly reduced recruitment of 
53BP1 to DSBs compared to non-treated control (non-treated: 84% vs. ATM inhibitor: 
27%, showing more than five 53BP1 foci/cell) (Figure 5-11A-C). These results were 
in agreement with previous reports that ATM activity was crucial for H2AX signal 




Consistent with Figure 5-9D & E, I found that ATR and DNAPK inhibitors didn’t 






Figure 5-10: H2AX signal reduction was caused by defective ATM activation in HGPS. (A). 
Western blotting analysis with anti-pATM(S1981), anti-ATM, anti-H2AX and anti-GAPDH 
antibodies on serum starvation synchronized normal and HGPS fibroblasts. Cells were pre-incubated 
with ATM inhibitor at indicated concentrations for 24h prior to Dox treatment. (B). quantification of 
relative pATM(S1981) band intensity (normalized to total ATM) and relative H2AX band intensity 
(normalized to GAPDH). (C). Western blotting analysis with anti-pCHK1(S345), anti-CHK1, anti-
H2AX and anti-GAPDH antibodies on normal and HGPS fibroblasts pre-incubated with indicated 
concentrations of ATR inhibitor for 24h prior to Dox treatment. (D). Western blotting with anti-
pDNAPKcs1(T2609), anti-DNAPKcs, anti-H2AX and anti-GAPDH antibodies on normal and HGPS 










Figure 5-11: Inhibition of ATM impairs 53BP1 recruitment upon Dox treatment. (A). 
Representative fluorescence images of H2AX and 53BP1 in normal fibroblasts pre-incubated with or 
without 10M ATM specific inhibitor prior to Dox treatment. Scale Bar: 5m. (B). Line profile 
analysis of (A), showing the reduced recruitment of 53BP1 to H2AX foci in ATM inhibitor treated 
fibroblasts. Green (H2AX) and red (53BP1) fluorescence intensities (y axis) were plotted against 
distance (x axis) along the yellow line in (A). Stars indicated strong co-localization of 53BP1 and 
H2AX. (C). Quantification of the percentage of thr population that displayed more than five 53BP1 
foci in control or ATM inhibitor treated fibroblasts. Results were presented as mean ± SEM.  ***P < 
0.001. 
 
Furthermore, to understand why the H2AX reduction in HGPS is G0/G1 phase 
specific, I checked the level of pATM in G0/G1 and S phase HGPS fibroblasts upon 
Dox treatment. As shown in Figure 5-12A & B, the immunofluorescence staining 
illustrated that ATM activation was significantly inhibited in G0/G1 phase but not in 
S phase HGPS fibroblasts, which was in high accordance with the observed 
differential levels of H2AX and NHEJ activation in G0/G1 and S phases HGPS cells 
(Figure 5-5 – 5-7). Together, these results indicate that ATM activation is responsible 
for the amplification of H2AX signals upon Dox treatment and that in G0/G1 phase 







Figure 5-12: ATM activation defect is cell cycle dependent in HGPS fibroblasts. (A). 
Representative fluorescence images of pATM (S1981) and BrdU staining in normal and HGPS 
fibroblasts after Dox treatment. G0/G1 and S phase were indicated by BrdU negative and positive 
staining respectively. Scale Bar: 5m. (B). Quantification of (A), showing relative pATM(S1981) 
green fluorescence intensity. More than 100 cells were randomly picked in each group for 
quantification except for S phase HGPS fibroblasts because very few S phase cells were found in that 





5.2.6 Loss of H3K9me3 contributes to impaired ATM activation in HGPS. 
It has been recently shown that histone H3 trimethylated on lysine 9 (H3K9me3) 
was crucial for ATM activation (Ayrapetov et al., 2014; Sun et al., 2009), in 
particular, the removal of H3K9me3 by SUV39h1 depletion completely blocked 
ATM activation upon DSBs (Sun et al., 2009). It is worth mentioning that the 
trimethyl mark of H3K9 is diluted during replication in the S phase, and the newly 
synthesized histones become fully methylated only in the next G1 phase (Zee et al., 
2012). In HGPS cells, a dramatic loss of H3K9me3 has been observed frequently 
(Kelley et al., 2011; McCord et al., 2013; Shumaker et al., 2006; Xiong et al., 2015). 
Based on this information, I hypothesized that loss of H3K9me3 in HGPS cells 
caused the consequent blockage of ATM activation, resulting in insufficient H2AX 
signals at the DSBs and delayed DNA damage repair.  
To test this hypothesis, I first examined the correlation between H3K9me3 and 
H2AX signals in normal and HGPS cells.  As shown in Figure 5-13A, I found that 
after Dox treatment cells with robust H2AX responses almost always displayed 
decent H3K9me3 staining, and weak H2AX staining was often observed in cells 
with decreased H3K9me3. Correlative analysis based on the fluorescence intensities 
of both indicated a significant positive correlation between H3K9me3 and H2AX in 
both normal and HGPS fibroblasts (Figure 5-13B). It has been previously established 
that premature senescence, chromatin disorganization and epigenetic abnormalities 
(loss of H3K9me3 and H3K27me3) worsen in HGPS cells as progerin accumulated 
with increased cellular passages (McClintock et al., 2006; McCord et al., 2013; 




H2AX phosphorylation also followed this pattern. To test this, I synchronized early, 
middle and late passage HGPS and normal control fibroblasts to G0/G1 phase, treated 
them with Dox and examined their levels of pATM and H2AX. In agreement with 
the previous report, H3K9me3 level was high and similar to the controls at early 
passage, but became gradually reduced at middle and late passages (Figure 5-13C) 
(Shumaker et al., 2006). Moreover, both pATM and H2AX signals displayed a 
similar pattern of deterioration in HGPS cells with increased cellular passages (Figure 
5-13D & E). These results support my hypothesis that the loss of H3K9me3, a well-
documented phenotype in HGPS cells, could play a role in blocking ATM activation 
and H2AX phosphorylation. 
To provide some insights into the down-regulation of H3K9me3 in HGPS cells, 
I first examined SUV39h1, the methyltransferase that methylates H3K9. My analysis 
indicated that the expression of SUV39h1 was similar in normal and HGPS cells 
(Figure 5-13C), suggesting that the reduction in H3K9me3 might not be caused by a 
decrease in its methylation. I next measured heterochromatin protein 1 (HP1), a 
heterochromatin binding protein that had been shown to play a crucial role in 
maintaining H3K9me3 (Zhang et al., 2015). Interestingly, HP1 displayed a passage 
dependent reduction in HGPS fibroblasts, suggesting that the down-regulation of 
HP might be responsible for H3K9me3 loss in HGPS (Figure 5-13C & E). 
Significantly, these reductions were accompanied by a passage dependent 
accumulation of progerin in HGPS, further supporting an inhibitory role of progerin 















Figure 5-13: Loss of H3K9me3 contributes to impaired ATM activation in HGPS. (A). Representative 
fluorescence images of H2AX and H3K9me3 in normal and HGPS fibroblasts after Dox treatment. 
Scale Bar: 5m. (B). Quantification of (A), showing the Spearman rank correlations between 
H3K9me3 green fluorescence intensity and H2AX red fluorescence intensity in normal and HGPS 
fibroblasts. More than 100 cells were randomly picked for quantification in each group. (C). Western 
blotting analysis with anti-H3K9me3, anti-SUV39h1, anti-HP1 and anti-GAPHD antibodies on 
normal and HGPS fibroblasts at early, middle and late passages respectively. (D). Western blotting 
analysis with anti-pATM(S1981), anti-ATM, anti-H2AX and anti-GAPDH antibodies on serum 
starvation synchronized normal and HGPS fibroblasts at early, middle and late passages after Dox 
treatment. (E). Quantification of (C) and (D), showing relative pATM(S1981) (normalized to ATM), 
H2AX, H3K9me3, SUV39h1 and HP1 (normalized to GAPDH) band intensities in normal and 




Figure 5-14: Progerin accumulates in HGPS fibroblasts with increased passage. (A). Western blotting 
analysis with anti-Lamin A/C and anti-GAPDH antibodies on normal and HGPS fibroblasts at early, 
middle and late passages, showing the passage dependent accumulation of progerin in HGPS. (B). 
Quantification of (A), showing the relative band intensity of progerin (normalized to GAPDH) in early, 





5.2.7 Methylene blue restores H3K9me3 and rescues ATM activation, H2AX 
signaling, and NHEJ deficiency in HGPS fibroblasts. 
Methylene blue (MB) has been previously shown by our group to enhance 
HP1 and H3K9me3 levels and rescue heterochromatin loss in HGPS fibroblasts 
(Xiong et al., 2015). Furthermore, MB treatment has been shown to maintain progerin 
level but increase its solubility in HGPS cells (Xiong et al., 2015). I were interested in 
examining whether MB treatment would be able to rescue the downstream defects of 
H3K9me3 loss, including the weakened ATM and H2AX phosphorylation and the 
delayed DNA damage repair in HGPS.  
Normal and HGPS fibroblasts were treated with 100nM MB for 30 days and 
then tested for ATM and H2AX response upon Dox treatment. As expected, after 30 
days of treatment, MB significantly increased HP1 and H3K9me3 levels in HGPS 
G0/G1 phase fibroblasts (Figure 5-15A). Importantly pATM (S1981) and H2AX 
responses were significantly restored in G0/G1 synchronized HGPS fibroblasts after 
MB treatment (Figure 5-15A). To test whether the up-regulation of H2AX responses 
by MB was sufficient to overcome NHEJ deficiency in HGPS, I measured 53BP1 
recruitment in MB treated HGPS fibroblasts. As shown in Figure 5-15B, 53BP1 was 
rapidly recruited to H2AX foci, suggesting a functional NHEJ in HGPS after MB 
treatment. Line profile analysis also confirmed the co-localization between 53BP1 
and H2AX in MB treated HGPS fibroblasts (Figure 5-15C). Next, I investigated 
whether NHEJ efficiency was restored in HGPS after MB treatment by examining 
H2AX foci turn over in MB treated normal and HGPS fibroblasts. As shown in 




drastically from 44±1.7/cell to 16±0.7/cell in MB treated HGPS fibroblasts. In 
contrast, non-treated HGPS fibroblasts exhibited a significant delay in DNA damage 
repair as shown by retaining a substantial amount of H2AX foci (31±1.1) after 
24hours recovery (Figure 5-15E). In comparison, normal fibroblasts showed active 
NHEJ with/without MB treatment (24h after Dox treatment, -MB: 16±0.5 and +MB: 
12±0.5) (Figure 5-15E). Taken together, these data provided additional support to my 
hypothesis that increasing H3K9me3 could promote ATM activation and H2AX 






Figure 5-15: Methylene blue restores H3K9me3 and rescues ATM activation, H2AX signaling and 
NHEJ in HGPS fibroblasts. (A). Western blotting analysis with anti-pATM(S1981), anti-ATM, anti-
H2AX, anti-HP1, anti-H3K9me3 and anti-GAPDH antibodies on normal and HGPS fibroblasts 
treated with or without MB for 30 days. Cells were treated with Dox to induce DSBs before analysis. 
(B). Representative fluorescence images of H2AX foci and 53BP1 foci in normal and HGPS 
fibroblasts treated with or without MB for 30 days. Cells were treated with Dox to induce DSBs before 
analysis.  Scale Bar: 5m. (C). Line profile analysis of (B), showing the robust recruitment of 53BP1 
to H2AX in MB treated HGPS fibroblasts. Green (H2AX) and red (53BP1) fluorescence intensities 
(y axis) were plotted against distance (x axis) along the yellow line in (B). Stars indicated strong co-
localization of 53BP1 to H2AX. (D). Representative fluorescence images of H2AX foci in normal 
and HGPS fibroblasts treated with or without MB for 30 days. Cells were then treated with Dox to 
induce DSBs and allowed to recover for indicated amounts of time before analysis. Scale Bar: 5m. 
(E). Quantification of (D), showing the number of H2AX foci in each nucleus at each time point. 
More than 100 cells were randomly picked for quantification in each group. Results were presented as 





5.3.1 H2AX response to DSBs is impaired in HGPS. 
As the most conspicuous histone modification at DSBs, H2AX plays a critical 
function in DDR (Bassing et al., 2002; Kinner et al., 2008; Paull et al., 2000). Loss of 
H2AX signals has been shown to disrupt the recruitment of NHEJ players to DSBs 
and compromise genome integrity (Bassing et al., 2002; Ward et al., 2003). To 
investigate H2AX signals in HGPS cells, I induced global DSBs in HGPS and 
normal control fibroblasts by DNA damaging agents. My results demonstrated that 
the G0/G1 phase HGPS fibroblasts displayed significantly reduced H2AX signals 




Importantly, weak H2AX response was associated with reduced recruitments of 
RIF1 and 53BP1, two critical NHEJ regulators (Figure 5-7), suggesting that the 
weakened H2AX signals affected normal NHEJ in HGPS cells during the G0/G1 
phase.  
Previous studies have reported an increased basal level of DNA damage in 
HGPS models (Liu et al., 2005; Liu et al., 2006; Liu et al., 2008; Osorio et al., 2011; 
Varela et al., 2005). In my study, I also observed an elevated basal count of H2AX 
foci in HGPS fibroblasts (Figure 5-1). This increase likely reflects a dysfunctional 
DNA damage repair and sustained DSBs in HGPS models. Different from the Dox-
induced widespread H2AX signals described in this paper, the basal H2AX signals 
are much more limited, which mark the naturally occurred DSBs under the normal 
condition. In this study, I applied Dox or CPT to induce global DSBs and studied the 
immediate H2AX responses after induction. My results revealed a weakened 
immediate H2AX response at DSBs, which consequently caused delayed NHEJ, 
sustained H2AX foci and compromised genome integrity. Thus, my study provided 
mechanistic insights into the previously described phenotype of increased basal level 
H2AX in HGPS (Liu et al., 2005; Liu et al., 2006; Liu et al., 2008; Osorio et al., 
2011; Varela et al., 2005). 
 
5.3.2 Reductions in H2AX response and ATM activity in HGPS cells are cell-
cycle dependent. 
To elucidate the upstream clue of weakened H2AX signals in HGPS, I 




and DNAPK (Burma et al., 2001; Kinner et al., 2008; Stiff et al., 2004; Ward and 
Chen, 2001). My experiments indicated that only ATM was activated upon Dox 
induction, which was responsible for H2AX signals (Figure 5-9 and Figure 5-10). 
Moreover, I found that ATM activation was inhibited in G0/G1 phase HGPS 
fibroblasts (Figure 5-12).  
Unlike G0/G1 phase cells, S phase HGPS fibroblasts displayed normal H2AX 
signals and ATM activation upon Dox induction (Figure 5-5). An intriguing question 
is why ATM activation is not blocked in the S phase HGPS cells? One possibility is 
that the chromatin compaction and organization are different between G0/G1 and S 
phase cells. For instance, during the process of DNA replication, chromatin opens up 
and renders a more flexible structure, which has been shown to favor the recruitment 
of DNA damage repair pathway proteins (Alabert and Groth, 2012). Supporting this 
idea, the previous study has demonstrated that “opening up” chromatin by depleting 
histone H1 or treating cells with histone deacetylase (HDAC) inhibitor TSA was able 
to significantly enhance H2AX signals upon DSBs (Murga et al., 2007). Apart from 
H2AX, alterations in chromatin structure also directly impact ATM activity. 
“Opening up” chromatin through TSA treatment has been shown to activate ATM 
either with or without the presence of DSBs (Bakkenist and Kastan, 2003; Lee, 2007). 
Thus, it is likely that the chromatin structure remodeling during S phase might 
facilitate ATM activation and phosphorylate H2AX upon DSBs, alleviating the 





5.3.3 The association of H3K9me3 loss and ATM activation in G0/G1 phase 
HGPS cells. 
Recent studies have highlighted the role of H3K9me3 in regulating ATM 
activation in response to DNA damage (Ayrapetov et al., 2014; Sun et al., 2009). 
Removal of H3K9me3 by knocking out its methyltransferase SUV39h1 has been 
shown to completely abolish ATM activation upon ionizing irradiation (Sun et al., 
2009). Interestingly, loss of the pericentric heterochromatin marker H3K9me3 is a 
major epigenetic abnormality in HGPS cells, which has been described by multiple 
independent groups (Kelley et al., 2011; Shumaker et al., 2006; Xiong et al., 2015). I 
found a significant positive correlation between the H3K9me3 level and H2AX 
signal strength in both normal and HGPS fibroblasts after Dox treatment (Figure 5-
13). Moreover, similar to H3K9me3, both the ATM activity and H2AX 
phosphorylation followed a trend of deterioration with increased cellular passage and 
accumulation of progerin in HGPS fibroblasts (Figure 5-13D & E and Figure 5-14).  
Based on these observations, I further hypothesized that restoration of 
H3K9me3 might rescue ATM functionality in HGPS cells. To test this hypothesis, I 
treated normal and HGPS fibroblasts with methylene blue (MB), a chemical that was 
recently shown to increase the solubility of progerin, enhance H3K9me3 level and 
rescue heterochromatin loss in HGPS fibroblasts (Xiong et al., 2015). Significantly, 
MB almost completely restored ATM activation in G0/G1 HGPS fibroblasts upon 
Dox treatment (Figure 5-15A). Moreover, downstream DNA damage response 
activities including H2AX response, 53BP1 recruitment and DNA damage repair 




observation that MB’s effect was mostly HGPS specific (Xiong et al., 2015), I found 
that MB treatment didn’t change NHEJ in normal fibroblasts (Figure 5-15). Based on 
these results, my study suggests a novel connection between the two prominent 
phenotypes in HGPS - H3K9me3 loss and NHEJ deficiency.  My results also provide 
mechanistic insights underlying the complex phenotypes in HGPS cells and suggest 
new therapeutic target to treat DNA damage repair deficiency and protect genome 

















































The research presented in this dissertation has three aims. To begin with, my 
initial goal was to elucidate the molecular mechanism underlying the frequently 
observed vascular smooth muscle cell loss phenotype in HGPS patients and animal 
models.  
The research presented in Chapter II & III started from the development and 
characterization of an in vitro SMC differentiation system based on iPSCs. I 
established this system to circumvent the problems associated with primary HGPS 
SMC culture and to acquire a workable amount of HGPS SMCs. To differentiate 
SMCs from iPSCs, I adopted a three step lineage specific differentiation protocol and 
generated HGPS and normal control SMCs with high efficiency (>80% expressing 
SMC specific markers) (Xie et al., 2007b). Characterization on these cells confirmed 
classic HGPS cellular phenotypes including proliferation defects and premature 
senescence. Moreover, I found that HGPS SMCs bear elevated basal level of cell 
death, which provided a plausible in vitro explanation for the in vivo vascular SMC 
loss phenotype.  
The mechanistic study revealed that HGPS SMC cell death was independent of 
Caspase 3 mediated apoptosis. Interestingly, PARP1, an important regulator involved 
in DNA damage repair and cellular homeostasis was found to be significantly down-
regulated in HGPS SMCs (Patel et al., 2011). I determined that progerin led to 
PARP1 down-regulation through interfering with its nuclear translocation. It has been 
previously reported that deletion or inhibition of PARP1 was lethal in HR deficient 




More importantly, HR has been shown to be impaired in HGPS fibroblasts, implying 
a potentially similar deficiency in HGPS SMCs (Liu et al., 2005). Based on these 
pieces of information, I hypothesized that down-regulation of PARP1 in HR deficient 
HGPS SMCs lead to genome instability, chromosome aberrations and cell death. 
Indeed, my data suggested that HR was completely inhibited in HGPS SMCs during 
S/G2 phase. Moreover, NHEJ, the error prone DSB repair pathway was over-
activated in HGPS SMCs during S/G2 phase. This mis-regulation of DSB repair 
pathways led to abnormal chromosome structure and cell death during mitosis. This 
mechanistic model is illustrated in Figure 6-1. Together, these results suggested that 
DNA damage repair deficiency was an important factor contributing to the SMC cell 







Figure 6-1: Working model of HGPS SMC cell death. The accumulation of membrane-associated 
progerin not only causes HR deficiency via an unknown mechanism, but also causes PARP1 down-
regulation, likely through interfering with PARP1 nuclear import. This PARP1 reduction results in the 
activation of the NHEJ pathway in the HR-deficient HGPS SMCs, leading to error-prone DNA repair, 
chromosome aberration, and mitotic catastrophe in HGPS SMCs. 
 
Chapter II & III emphasized the importance of proper regulation of NHEJ and 
HR during different cell cycle phases to genome integrity and cellular homeostasis 
(Branzei and Foiani, 2008). Based on those results, in the second aim, I proposed to 
fully characterize the cell cycle dependent activation pattern of NHEJ and HR in 
HGPS cells upon DSBs. The research presented in Chapter IV revealed a completely 
disrupted cell cycle dependent regulation of NHEJ and HR in HGPS fibroblasts. In 
detail, HR (indicated by BRCA1 & Rad51 recruitment) was almost undetectable in 
G0/G1 phase and significantly impaired in S/G2 phase HGPS fibroblasts. NHEJ 
(indicated by RIF1), on the other hand, was drastically delayed during the G0/G1 
phase, but active in S/G2 phase HGPS fibroblasts (Figure 4-8). These results were in 
agreement with my previous findings on HGPS SMCs. The mis-regulation of NHEJ 
and HR could potentially induce various cellular defects in HGPS. For example, 
defective HR and active NHEJ during S/G2 HGPS SMCs undermine genome 
integrity and contribute to chromosome aberrations and mitotic catastrophe (See in 
Chapter III). On the other hand, deficient NHEJ during G0/G1 phase has been 
proposed to induce premature senescence in HGPS fibroblasts (Krishnan et al., 2011; 
Liu et al., 2012; Liu et al., 2005; Liu et al., 2013a; Liu et al., 2013b).  
In aim three, I continued to investigate the molecular mechanism underlying 




signal up-stream of NHEJ: H2AX response. H2AX is not only a popular DSB 
marker, but also an important signal protein that facilitates down-stream DNA repair 
(Kinner et al., 2008). Deletion of H2AX signal has been shown to impair the 
recruitment of a variety of DNA repair factors, including 53BP1, an important player 
in NHEJ (Bassing et al., 2002; Kinner et al., 2008; Mah et al., 2010). To investigate 
H2AX signaling in HGPS upon DNA damage, I introduced DSBs by Doxorubicin 
treatment. My results showed that H2AX response followed a cell cycle dependent 
reduction in HGPS fibroblasts upon DSBs. HGPS H2AX response was significantly 
reduced during the G0/G1 phase, but almost completely unaffected in S/G2 phase. 
This cell cycle dependent response of H2AX was highly accordant with NHEJ 
activation pattern in HGPS. Reduced H2AX response was correlated with delayed 
recruitment of 53BP1 and RIF1 and also delayed DNA damage repair in HGPS as 
indicated by undetectable 53BP1 or RIF1 co-localized with weak H2AX foci in 
HGPS. These results suggested a role of H2AX signal deficiency in NHEJ mis-
regulation. In the upstream, H2AX reduction was caused by a reduced ATM 
activation during the G0/G1 phase in HGPS fibroblasts. Inhibition of ATM, but not 
ATR or DNAPKcs was able to suppress H2AX response upon Dox treatment. 
Interestingly, ATM activation was normal in S/G2 phase HGPS fibroblasts. This 
activation pattern was consistent with H2AX response and NHEJ in HGPS. Finally, 
I found that ATM inactivation was highly correlated with the H3K9me3 loss, a 
classic epigenetic alteration in HGPS. Restoration of H3K9me3 through methylene 
blue treatment was able to rescue ATM inactivation, H2AX signal reduction and 




underlying HGPS NHEJ abnormality and provided a novel connection between the 
two prominent phenotypes (H3K9me3 loss and NHEJ deficiency) and mechanistic 
insights underlying the complex phenotypes in HGPS cells. 
 
 
6.2 Future perspectives 
The work presented in this dissertation not only established a plausible model to 
recapitulate HGPS vascular smooth muscle cell pathology, but also identified PARP1 
down-regulation and disrupted HR and NHEJ as important players in HGPS SMC 
cell death. Furthermore, this dissertation investigated the molecular mechanism 
underlying HGPS NHEJ deficiency and provided a novel connection between the 
classic H3K9me3 loss phenotype and defective NHEJ in HGPS cells. Despite that the 
conclusions from this dissertation deepened our understanding of the HGPS SMC 
loss phenotype and HGPS DNA damage repair deficiency, there are still important 
questions remaining to be addressed.  
Question 1: Does in vitro mechanism pertain to in vivo phenotype? In 
Chapter II & III, I established a 2D differentiation system to mimic the in vivo SMC 
loss phenotype and proposed a mechanistic model (Figure 6-1) to explain HGPS 
SMC cell death. However, whether these findings faithfully recapitulated in vivo 
situations remains unclear. Therefore, a validation of their applicability within a more 
physiological environment is important. BACG608G and LmnaG609G HGPS mouse 
models provide a valuable tool to test these mechanistic models in vivo. This question 




between vessel tissues from HGPS and normal control mouse models is necessary. To 
do this, one could perform western blotting and immunohistochemistry (IHC) 
analysis to detect PARP1 level on aortic tissue samples from BAC G608G mice and 
control mice at various ages. In IHC experiments, the intensity of PARP1 signal in 
each SMC will negatively correspond with the progerin signal intensity to establish a 
correlation between progerin and PARP1 at single cell level in vivo. Second, to assay 
DNA damage repair in vivo, one could isolate primary SMCs from BAC G608G mice 
and measure HR and NHEJ efficiencies as described in Chapter III.  
Question II: What is the connection between HGPS SMC loss and HGPS 
cardiovascular pathology? Despite that BACG608G and LmnaG609G mouse models are 
able to phenotypically recapitulate the vascular SMC loss phenotype in HGPS patients, they 
fail to display the connection between this phenotype and the cardiovascular pathology in 
progeria. This drawback is caused by their incapability to capture the onset and progression 
of SMC loss or to establish a causation relationship between SMC loss and other 
cardiovascular defects. Based on this notion, in vivo real time observation of SMC loss and 
other cardiovascular physiological features is a good approach to inform us about the 
connection between vascular SMC loss and cardiovascular pathogenesis in HGPS. Moreover, 
real time monitoring vascular SMC loss will allow researchers to more conveniently test new 
drug therapies towards HGPS. Technically, I can adopt the in vivo bioluminescence imaging 
technology to visualize vessel development and SMC loss in a real time manner.  By, using a 
Firefly luciferase and GFP reporter driven by SMC marker specific promoter, such as SM22 
and smMHC promoter, I will be able to specifically observe the changes in vascular SMC 
number by measuring bioluminescence intensity, under normal or HGPS genetic background.  
Question III: Are there additional methods to mimic HGPS SMC loss under 




reconstruct physiological environment is to engineer the 2D differentiated HGPS SMCs into 
3D tissue engineered blood vessels (TEBVs) (Fernandez et al., 2014). These vessels are 
cultured in a fluid perfusion system, which allows scientists to recreate blood flow in TEBVs 
in vitro. Compared to HGPS animal models, HGPS TEBVs not only could faithfully 
recapitulate physiological conditions, but also are easier to generate, maintain and test. In 
collaboration with Dr. George Truskey at Duke University, we established a protocol to 
generate HGPS and control TEBVs from HGPS SMCs. 
Question IV: Is HGPS SMC cell death rescuable? My mechanistic model suggested 
that progerin induced PARP1 down-regulation contributed to HGPS SMC cell death (Figure 
6-1). Therefore, it would be interesting to over express PARP1 in HGPS SMCs and examine 
its effect on HGPS SMC survival.  
Question V: What is the mechanism underlying HGPS HR deficiency? In 
chapter IV, I showed that HR was significantly impaired in S/G2 phase HGPS 
fibroblasts. Yet, the underlying molecular mechanism is still largely unknown. My 
preliminary data suggested that protein and mRNA levels of Rad51 and BRCA1 were 
significantly reduced in HGPS fibroblasts (Figure 4-5). However, it has been 
previously shown that S/G2 phase cells expressed higher amount of HR associated 
factors including BRCA1 and Rad51. Thus, it was unclear whether this reduction 
reflected a real protein down-regulation or was an artifact caused by a reduced 
percentage of S/G2 phase population in HGPS fibroblasts. To solve this problem, it is 
worthy to compare the level of HR factors between HGPS and normal control cells 
during S/G2 phase.  
Question VI: What is the potential of Methylene blue as an HGPS 




According to our previous research, methylene blue possessed significant 
beneficial effect to HGPS fibroblasts and was able to promote HGPS cellular 
proliferation, reduce HGPS ROS level and improve HGPS mitochondrial function 
and restore HGPS heterochromatin abnormalities. Moreover, in my research, I 
discovered that methylene blue could rescue the DSB repair defects in HGPS cells. 
Based on these beneficial effects, it would be interesting to test methylene blue’s 
potential as a therapeutic approach to treat HGPS. 
Elucidating the above questions is beyond the scope of this dissertation, but will 
significantly expand our knowledge about the HGPS SMC cell loss, cardiovascular 




























































7.1 Chapter II & III 
 
7.1.1 Plasmids 
Retroviral vectors encoding human KLF4, SOX2, OCT4, and C-MYC were 
previously described in (Takahashi et al., 2007). pEGFPC1- Hutchinson–Gilford (HG) 
(progerin) and pEGFP-C1-lamin A (LA) were constructed based on pEGFP-C1 
vector (Clontech). DsRed-HG and DsRed-LA were constructed based on 
DsRedmonomer-C1 vector (Clontech). pMKO.1-progerin-shRNA retroviral plasmid 
was constructed based on pMKO.1 vector (Addgene). pEGFP-N3-Poly(ADP-ribose) 
polymerase 1 (PARP1) was kindly provided by Guy Poirier at Université Laval, 
Quebec, Canada.  
 
7.1.2 RT-Quantitative PCR and Primers 
RNA samples were extracted from normal and Hutchinson–Gilford progeria 
syndrome (HGPS) smooth muscle cells (SMCs) with the Qiagen RNAeasy kit, and 
reverse transcribed into cDNA with the iScript Advanced cDNA Synthesis kit (170–
8842; Bio-Rad). RT-quantitative PCR (RT-qPCR) was conducted in triplicate using 
SYBR Green Supermix (170–8880; Bio-Rad) on a CFX96 real-time system (C1000 
Thermal Cycler; Bio-Rad). Primers for amplifying Endo-Sox2, Endo-Oct3/4, and 
Nanog were previously described (Takahashi et al., 2007). Primers for amplifying 
SMC–α-actin (SMA), calponin, smMHC, and SM22-α were described (Xie et al., 
2007b). As an internal control, human GAPDH primer was purchased from real-time 




reverse transcriptase (hTERT), Bax, PARP1 are listed below: human p16ink4a (F: 5′
-TAGTTACGGTCGGAGGCCGAT; R: 5′ -CTTTCAATCGGGGATGTCTGAG); 
human TERT (F: 5 ′ - TGTGCACCAACATCTACAAG; R: 5 ′ -
GCGTTCTTGGCTTTCAGGAT); human Bax (F: 5 ′ -
GTTTCATCCAGGATCGAGCAG; R: 5′-CATCTTCTTCCAGATGGTGA); and 
human PARP1 (F: 5 ′ -GACCTGAAGGAGCTACTCATC; R: 5 ′ -
TTTCTCGGAATTCCTTTGGGG). 
 
7.1.3 SMC Differentiation from Induced Pluripotent Stem Cells 
To differentiate SMCs from induced pluripotent stem (iPS) cells, I adopted a 
three-step indirect differentiation protocol with minor modifications (2). Briefly, 
embryoid bodies (EBs), generated from normal or HGPS-iPSCs, were cultured in 
suspension for 5–7 d and then seeded onto 0.1% gelatin-coated dishes for EB 
outgrowth formation. After 10 d, outgrowth cells were detached and reseeded onto 
Matrigel-coated plates in SMC growth medium (Lonza) and further cultured as pre-
SMCs for 2 wk. The pre-SMCs can be frozen and stored for future differentiation. 
After 2 wk of induction, the HGPS and normal pre-SMCs were trypsinized with 
TrypLE Express (Life Sciences) and re-plated at a density of 1 × 106 cells per 10-cm 
dish (precoated by 0.1% gelatin) in SMC differentiation medium [DMEM, supplied 
with 5% (vol/vol) FBS] to initiate SMC differentiation. SMCs were grown for 28 d in 






7.1.4 Western Blotting Analysis 
Whole cell lysate was obtained by treating cell pellets with Laemmli buffer 
(161–0737; Bio-Rad), containing 5% (vol/vol) β-mercaptoethanol. Protein samples 
were then separated in 10% or 15% SDS/PAGE gels and transferred onto a 
nitrocellulose membrane (Bio-Rad) for primary and secondary antibody incubation as 
described. Signal intensity was quantified using ImageJ software (National Institutes 
of Health, NIH). 
 
7.1.5 Contractility Assay and Ca2+ Image 
SMC contractility was tested by angiotensin II treatment. Briefly, normal and 
HGPS SMCs were seeded onto gelatin-coated 35-mm glass-bottom dishes 
(NC0409658; Fisher Scientific) at days 14 and 21. Twenty-four hours later, cells were 
treated with 10 μM angiotensin II and phase contrast pictures were taken every 10 
min until 30 min after treatment. Pictures were taken with a Zeiss AX10 microscope. 
To image Ca2+ flow in SMCs, flow3 Ca2+ fluorescent indicator (Invitrogen) was 
adopted. Briefly, normal and HGPS SMCs were washed with standard tyrode solution 
(100502-380; VWR) and incubated with 2 μM fluo-3-Ca2+ indicator [diluted in 
tyrode solution containing 0.02% Pluronic F-127 (8409400; Fisher Scientific)] at 
room temperature for 20 min. Cells were then washed with tyrode solution three 
times and imaged for angiotensin II-stimulated Ca2+ flow signal by UltraVIEW VoX 
system (PerkinElmer) attached to an inverted microscope (Eclipse Ti; Nikon) as 





7.1.6 SMC Differentiation Efficiency Test 
SMC cells were detached from plates at day 14, washed with PBS, fixed in 4% 
(vol/vol) paraformaldehyde in PBS for 20 min, and permeabilized with 0.2% Triton 
X-100 in PBS for 5 min. Cells were then incubated with primary anti-SMA (Sigma) 
or anti-calponin (Millipore) antibody overnight at 4 °C. Samples without primary 
antibodies were included as blank controls. Alexa Fluor 488-tagged secondary 
antibody (Life Sciences) was then added to all samples for 1 h at room temperature. 
Finally, samples were rinsed with PBS and scored by flow cytometry (FACSCanto II; 
BD). Positive signals were determined according to the blank controls. 
 
7.1.7 Senescence-Associated β-Galactosidase Activity Assay 
Senescence-Associated β-Galactosidase Activity Assay. SA–β-gal activity was 
assayed weekly on normal and HGPS SMCs according to the manufacturer’s protocol 
(9860; Cell Signaling). Images were taken with a Zeiss AX10 microscope. Cell Cycle 
Analysis. Cell cycle analysis was conducted on normal and HGPS SMCs weekly 
during SMC differentiation. Cells were harvested, rinsed with PBS, and resuspended 
in 0.5 mL PBS. Then, 4.5 mL of 70% (vol/vol) ice-cold ethanol was added to the cell 
suspension for fixation. This mixture was incubated on ice for 10–15 min. Then cells 
were pelleted, rinsed with PBS, and re-suspended in propidium iodide (PI) DNA 
staining buffer (50 μg/mL PI and 100 μg/mL DNase-free RNase in PBS) for 30 min 
at 37 °C. Flow cytometry was performed with FACS CantoII (BD) and the data were 





7.1.8 PI-annexin V Assay 
PI-annexin V Assay. PI-annexin V assay was performed weekly on normal and 
HGPS SMCs according to the manufacturer’s protocol (556547; BD). Briefly, normal 
and HGPS SMCs were harvested and rinsed with PBS (with extreme care to 
minimize cell injury). Then cells were re-suspended and stained with 100 μl of 1× 
annexin V binding buffer containing 5 μl of annexin V and 5 μL of PI for 25 min in 
the dark at room temperature. After the staining, these samples were scored by FACS 
CantoII (BD) and the data were processed by FlowJo software. 
 
7.1.9 Caspase 3 Activity Assay 
Caspase 3 activity was assayed on normal and HGPS SMCs using a caspase 3 
Colorimetric Activity kit following instructions from the manufacturer (APT165; 
Millipore). Briefly, for basal caspase 3 activity measurement, differentiated SMCs at 
day 21 were harvested and lysed in lysis buffer. Protein concentration was determined 
by Nanodrop 2000 spectrophotometer (Thermo Scientific), and different amounts of 
protein samples were added into 96-well plates with a caspase 3 substrate. After a 24-
h incubation at 37 °C, these mixtures were measured for light absorbance at 405 nm 
by SpectraMax M5e (Molecular Devices). To measure caspase 3 activity upon 
apoptotic induction, normal and HGPS SMCs were first treated with 20 μM 





7.1.10 Clonogenic Assay 
Normal and HGPS fibroblasts (passage 16) were seeded into six-well plates at a 
density of 500 cells per well. Cells were incubated for 5–7 h. Then, fresh fibroblast 
medium with indicated concentration of PARP1 inhibitor (AZD2281; Olaparib) was 
added to the cells for 72 h. After the inhibitor was removed, cells were further 
cultured for 10–14 d to allow colony formation. To count the number of colonies, 
cells were stained with Hoechst 33342 and cell clusters that contain more than 20 
cells were counted as a positive colony. The number of colonies in each treatment 
was normalized to untreated control to calculate the survival rate. 
 
7.1.11 SMC Transfection 
Electroporation was performed with a Amaxa NHDF Nucleofector kit (F-09376; 
Lonza) on a Nucleofector 2b machine (Lonza). Roughly 1 × 106 normal SMC cells 
were collected and transfected with 2 μg pEGFP-HG or pEGFP-LA for a single 
transfection, and with 0.5 μg pEGFP-N3-PARP1 plus 1.5 μg DsRed-LA, DsRed-HG, 
or DsRed-HG-SSIM, a nonfarnesylatable mutant of progerin that carries a cysteine to 
serine mutation on the CSIM motif at the C terminus for a double transfection. 
Seventy-two hours after transfection, cells were examined by Western 
immunoblotting or with confocal microscopy (Zeiss LSM 710). For 
farnesyltransferase inhibitor (FTI) treatment, after SMCs were transfected, 2 μM FTI 
was immediately applied to the transfected cells, and cells were examined by 






7.1.12 Immunofluorescence Quantification 
To quantify immunofluorescence intensity, pictures were analyzed by ImageJ 
software (NIH) using color histogram function. Fluorescent intensities were 
subtracted with background signals and plotted. ForRan gradient (Ran N/C) 
quantification, fluorescent signals of both nuclear and cytoplasmic Ran were 
quantified. To quantify immunofluorescence intensity, pictures were analyzed by 
ImageJ 
 
7.1.13 Quantification of DNA Damage and HR Repair Efficiency 
Cells were seeded 2 d before CPT treatment and fixed and permeabilized at 
various time points (10 min, 30 min, 120 min, and 720 min) post-CPT treatment. 
Immunofluorescence was conducted as follows. Fixed cells were incubated in 
blocking buffer [either 5% (vol/vol) donkey serum or 4% (vol/vol) BSA in TBS] for 1 
h, and co-stained with anti-γH2AX and anti-Rad51 antibodies for 2–3 h at room 
temperature. Corresponding secondary antibodies were then applied for 1 h before 
mounting. Images were taken by a Zeiss LSM 710 confocal microscope and analyzed 
by ImageJ software (NIH). The numbers of γH2AX foci in each normal or HGPS 
SMC cell were counted using the “find maxima” function. Only those Rad51 foci that 
colocalized with γH2AX foci were scored. More than 100 nuclei were analyzed at 







7.1.14 BrdU Pulse-Chase Assay 
Normal and HGPS SMCs were incubated with SMC differentiation medium 
containing 10 μM BrdU for 18 h. Upon BrdU removal, cells were incubated and fixed 
at denoted time points. To visualize BrdU, cells were treated with 2 M HCl before 
blocking buffer to open up DNA double strand and to expose the BrdU epitope. Cells 
were then processed with the standard immunofluorescence protocol using the anti-
BrdU antibody. Fluorescence images were taken and analyzed with a Zeiss AX10 
microscope.  
 
7.1.15 Life cell imaging 
Normal and HGPS SMCs were seeded in 35-mm glass-bottom dishes 
(NC0409658; Fisher Scientific) and imaged by the UltraVIEW VoX system 
(PerkinElmer) attached to an inverted microscope (Eclipse Ti; Nikon) as previously 
described (Fernandes et al., 2011). 
 
 
7.2 Chapter IV & V 
 
7.2.1 Cell culture 
Primary HGPS human skin fibroblast cells that carry the classic 1824 C->T 
mutation (HGADFN167) and normal control cells (HGFDFN168, father of 
HGADFN167) were obtained from Progeria Research Foundation (PRF) and cultured 




split at a ratio of 1:2 at 95% confluency. Normal and HGPS fibroblasts at passages 




Drugs used in this study are listed as below: Doxorubicin (Dox, Sigma), 
Camptothecin (CPT, Sigma), ATM specific inhibitor (KU55933, Selleck Chem), 
ATR specific inhibitor (VE-821, Selleck Chem), DNAPK specific inhibitor (NU7441, 
Selleck Chem) and Methylene Blue (MB; Acros Organics). 
 
7.2.3 Antibodies 
Antibodies used in western blotting and immunofluorescence analysis were 
obtained from the following sources: mouse anti-lamin A/C (Mab3211, Millipore), 
mouse anti-H2AX (05-636, Upstate), rabbit anti-H2AX (ab11174, Abcam), rabbit 
anti-H2AX (2595, cell signaling), mouse anti- -tubulin (DM1, Santa Cruz), mouse 
anti-GAPDH (ab8245, Abcam), mouse anti-BrdU (555627, BD Pharmingen), rabbit 
anti-RIF1 (A300-568A, Bethyl Laboratory), rabbit anti-53BP1 (sc-22760, Santa 
Cruz), rabbit anti-ATM (ab32420, Abcam), rabbit anti-pATM (S1981) (ab81292, 
Abcam), mouse anti-DNAPK (sc-390495, Santa Cruz), mouse anti-pDNAPK (T2609) 
(ab18356, Abcam), mouse anti-CHK1 (sc-8408, Santa Cruz), rabbit anti-
pCHK1(S345) (2341S, Cell Signaling),  rabbit anti-H3K9me3 (ab8898, Abcam), 






7.2.4 G0/G1 phase synchronization & Cell cycle analysis 
Passage-matched normal and HGPS fibroblasts were cultured in serum free 
MEM (Life Technologies) medium, supplemented with 2mM L-Glutamine (Life 
Technologies), for 24h for G0/G1 phase synchronization. Cell cycle analysis was then 
performed as previously described to examine the effect of serum starvation(Zhang et 
al., 2014). Briefly, normal and HGPS fibroblasts were harvested by TrypLE Express 
(Life Technologies) and washed with PBS (HyClone). Cell pellets were re-suspended 
in 0.5ml PBS and then added with 4.5ml 70% (vol/vol) ice-cold ethonal. The mixture 
was incubated for 10-15min at 4°C, washed with PBS and then re-suspended in 50l 
propidium iodide (Invitrogen) staining buffer (50g/ml propidium iodide and 
100g/ml DNAse-free RNAse in PBS). The mixture was then allowed to incubate for 
30min at 37°C. Flow cytometry was performed with FACS CantoII (BD) and cell 
cycle data analysis was performed with FlowJo software. 
 
7.2.5 Doxorubicin, Camptothecin and kinase inhibitor treatment 
For immunofluorescence staining analysis, 1M Doxorubicin or 20M 
Camptothecin were applied on passage-matched normal and HGPS fibroblasts 
(G0/G1 synchronized or unsynchronized) for 1h. Cells were then allowed to recover 
for 10min (or as indicated in time course experiments) before fixation. For western 
blotting analysis, 0.5M Doxorubicin or 50M Camptothecin were applied on 
passage-matched normal and HGPS fibroblasts for 2h before harvest. For kinase 




applied to passage-matched normal and HGPS fibroblasts at indicated concentrations 
for 24h prior to Doxorubicin treatment.  
 
7.2.6 Methylene blue treatment 
Methylene blue treatment was conducted as previously described (Xiong et al., 
2015). Briefly, MB was dissolved in PBS and added into growth medium at a final 
concentration of 100nM. Middle passage normal and HGPS fibroblasts were cultured 
in MB containing medium and passaged at 95% confluency. Cells were treated with 
MB for 30 days before analysis. 
 
7.2.7 Immunofluorescence staining 
Passage-matched normal and HGPS fibroblasts were seeded in chamber slides 
(BD Falcon) for immunofluorescence staining. Cells were fixed with 4% PFA/PBS 
for 25-30min, permeabilized with 0.5% Triton X-100 (EMD chemicals Inc.) for 5min 
and then blocked with 4% BSA/TBS for 1h at room temperature. Cells were then 
incubated with primary antibodies for overnight at 4°C. Corresponding secondary 
antibodies were then applied for 1h at room temperature. Fluorescence Images were 
taken by Zeiss LSM 710 confocal microscope.  
 
7.2.8 BrdU labeling 
For BrdU labeling, cells were pre-incubated with 10M BrdU (BD Biosciences) 
for 30min before Doxorubicin treatment. To visualize BrdU, cells were treated with 




then proceeded with standard immunofluorescence staining protocol with anti-BrdU 
antibody. Fluorescence images were taken by Zeiss LSM 710 confocal microscope.  
 
7.2.9 Fluorescence image analysis 
Fluorescence signal intensity was quantified through the “color histogram” 
function of Image J software (National Institute of Health, NIH). Fluorescence 
intensities were subtracted with background signals and plotted. The number of DNA 
damage associated foci (H2AX, RIF1 or 53BP1) was counted through the “find 
maxima” function of Image J software. Average intensity of individual foci was 
calculated as the ratio between total fluorescence intensity and the number of foci in 
each nucleus. Line profile analysis was conducted through the “Line profile” plugin 
of Image J software. 
 
7.2.10 Western blotting analysis 
Western blotting analysis was performed as previously described (Zhang et al., 
2014). Briefly, cells were directly lysed in Laemmli buffer (161–0737; Bio-Rad), 
containing 5% (vol/vol) β-mercaptoethanol. Protein samples were separated in 7.5% 
or 10% SDS-PAGE gels and transferred onto nitrocellulose membrane (Bio-Rad). 
Membranes were blocked with 5% milk in TBST and then incubated with primary 
antibodies for overnight at 4°C. Protein band intensities were quantified through 





7.2.11 Statistical analysis 
Two-tailed Student t test was used to analyze difference between normal and 
HGPS. A p value ≤ 0.05 was considered as significant. Statistical analysis was 
conducted through GraphPad Prism 5.0 software. 
 
7.2.12 Correlation analysis 
Spearman rank correlation analysis was performed to capture the association 
between H3K9me3 and H2AX signals and estimate the correlation coefficients. I 
used correlation functions in R to perform the analysis and ggplot2 package to make 





























Besides the above study, I am also involved in designing two additional projects: 
 
I. The roles of microtubule in nuclear morphology maintenance 
Nuclear blebbing is a hallmark of HGPS cellular phenotypes (Capell and 
Collins, 2006). Besides nuclear lamina meshwork, cytoskeleton network is also 
involved in nuclear structure maintenance (Starr and Fridolfsson, 2010). For example, 
microtubules have been shown to mediate nuclear lobulation in granulopoesis (Olins 
and Olins, 2004). Microtubules are also connected with the nuclear lamina meshwork 
through LINC complex, a protein complex that spans across the nuclear envelope and 
bridge between nuclear lamina and cytoskeleton network (Starr and Fridolfsson, 
2010). This information suggest that microtubules play a role in regulating nuclear 
morphology. In this project, we aimed to investigate the effect of lamin A-
microtubule interaction on nuclear morphology maintenance.  
 
II. Development of tissue engineered blood vessels (TEBVs) from iPSC 
differentiated SMCs 
As discussed in 6.2 Question III, TEBV is a plausible system to mimic HGPS 
SMC loss under physiological conditions. To realize HGPS TEBVs, I collaborated 
with Dr. George Truskey at Duke University. In this project, we were able to 




physiological, biochemical, molecular and cellular tests to validate our in vitro 
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